{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T03:52:21Z","timestamp":1791863541220,"version":"4.3.4"},"reference-count":241,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T00:00:00Z","timestamp":1749513600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T00:00:00Z","timestamp":1749513600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Deliv. and Transl. Res."],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s13346-025-01881-1","type":"journal-article","created":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T16:26:47Z","timestamp":1749572807000},"page":"45-75","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Nanoparticle-based approaches for vascular inflammation in managing hypertension: advancing molecular mechanisms and treatment strategies"],"prefix":"10.1007","volume":"16","author":[{"given":"Althaf Umar","family":"K P","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anagha R.","family":"Anil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9861-0461","authenticated-orcid":false,"given":"Sreeja C.","family":"Nair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2655-846X","authenticated-orcid":false,"given":"Kanthlal","family":"S K","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,10]]},"reference":[{"key":"1881_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12916-023-02925","volume":"21","author":"J Sun","year":"2023","unstructured":"Sun J, Qiao Y, Zhao M, Magnussen CG, Xi B. Global, regional, and national burden of cardiovascular diseases in youths and young adults aged 15\u201339 years in 204 countries\/territories, 1990\u20132019: a systematic analysis of Global Burden of Disease Study 2019. BMC Med. 2023;21:1\u201315. https:\/\/doi.org\/10.1186\/S12916-023-02925.","journal-title":"BMC Med"},{"key":"1881_CR2","doi-asserted-by":"publisher","first-page":"100456","DOI":"10.1016\/J.IJCCHD.2023.100456","volume":"13","author":"J Sabatino","year":"2023","unstructured":"Sabatino J, Avesani M, Sirico D, Reffo E, Castaldi B, Bassareo P, et al. Systemic hypertension in adults with congenital heart diseases. Int J Cardiol Congenit Heart Dis. 2023;13:100456. https:\/\/doi.org\/10.1016\/J.IJCCHD.2023.100456.","journal-title":"Int. J Cardiol Congenit Heart Dis"},{"key":"1881_CR3","doi-asserted-by":"publisher","first-page":"2749","DOI":"10.2147\/PPA.S368784","volume":"16","author":"SM Hamrahian","year":"2022","unstructured":"Hamrahian SM, Maarouf OH, F\u00fcl\u00f6p T. A critical review of medication adherence in hypertension: barriers and facilitators clinicians should consider. Patient Prefer Adherence. 2022;16:2749. https:\/\/doi.org\/10.2147\/PPA.S368784.","journal-title":"Patient Prefer Adherence"},{"key":"1881_CR4","doi-asserted-by":"publisher","first-page":"1098725","DOI":"10.3389\/FIMMU.2022.1098725\/BIBTEX","volume":"13","author":"Z Zhang","year":"2023","unstructured":"Zhang Z, Zhao L, Zhou X, Meng X, Zhou X. Role of inflammation, immunity, and oxidative stress in hypertension: new insights and potential therapeutic targets. Front Immunol. 2023;13:1098725. https:\/\/doi.org\/10.3389\/FIMMU.2022.1098725\/BIBTEX.","journal-title":"Front Immunol"},{"key":"1881_CR5","doi-asserted-by":"publisher","first-page":"798958","DOI":"10.3389\/FMED.2021.798958\/BIBTEX","volume":"8","author":"G Gallo","year":"2022","unstructured":"Gallo G, Volpe M, Savoia C. Endothelial dysfunction in hypertension: current concepts and clinical implications. Front Med (Lausanne). 2022;8:798958. https:\/\/doi.org\/10.3389\/FMED.2021.798958\/BIBTEX.","journal-title":"Front Med (Lausanne)"},{"key":"1881_CR6","doi-asserted-by":"publisher","first-page":"6624","DOI":"10.3390\/MOLECULES28186624","volume":"28","author":"S Malik","year":"2023","unstructured":"Malik S, Muhammad K, Waheed Y. Emerging applications of nanotechnology in healthcare and medicine. Molecules. 2023;28:6624. https:\/\/doi.org\/10.3390\/MOLECULES28186624.","journal-title":"Molecules"},{"key":"1881_CR7","doi-asserted-by":"publisher","unstructured":"Mall J, Naseem N, Haider MdF, Rahman MA, Khan S, Siddiqui SN. Nanostructured lipid carriers as a drug delivery system: a comprehensive review with therapeutic applications. Intell Pharm. 2024. https:\/\/doi.org\/10.1016\/J.IPHA.2024.09.005.","DOI":"10.1016\/J.IPHA.2024.09.005"},{"key":"1881_CR8","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.3390\/MOLECULES29122873","volume":"29","author":"ASR Pang","year":"2024","unstructured":"Pang ASR, Dinesh T, Pang NYL, Dinesh V, Pang KYL, Yong CL, et al. Nanoparticles as drug delivery systems for the targeted treatment of atherosclerosis. Molecules. 2024;29:2873. https:\/\/doi.org\/10.3390\/MOLECULES29122873.","journal-title":"Molecules"},{"key":"1881_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12951-024-02892-9","volume":"22","author":"X Cong","year":"2024","unstructured":"Cong X, Zhang Z, Li H, Yang YG, Zhang Y, Sun T. Nanocarriers for targeted drug delivery in the vascular system: focus on endothelium. J Nanobiotechnol. 2024;22:1\u201329. https:\/\/doi.org\/10.1186\/S12951-024-02892-9.","journal-title":"J Nanobiotechnol"},{"key":"1881_CR10","doi-asserted-by":"publisher","first-page":"101536","DOI":"10.1016\/J.SMIM.2021.101536","volume":"56","author":"N MacRitchie","year":"2021","unstructured":"MacRitchie N, Di Francesco V, Ferreira MFMM, Guzik TJ, Decuzzi P, Maffia P. Nanoparticle theranostics in cardiovascular inflammation. Semin Immunol. 2021;56:101536. https:\/\/doi.org\/10.1016\/J.SMIM.2021.101536.","journal-title":"Semin Immunol"},{"key":"1881_CR11","doi-asserted-by":"publisher","first-page":"e20230018","DOI":"10.1002\/INMD.20230018","volume":"1","author":"SL Gaytan","year":"2023","unstructured":"Gaytan SL, Beaven E, Gadad SS, Nurunnabi M. Progress and prospect of nanotechnology for cardiac fibrosis treatment. Interdiscip Med. 2023;1:e20230018. https:\/\/doi.org\/10.1002\/INMD.20230018.","journal-title":"Interdiscip Med"},{"key":"1881_CR12","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.jphs.2015.09.002","volume":"129","author":"Y Zhao","year":"2015","unstructured":"Zhao Y, Vanhoutte PM, Leung SWS. Vascular nitric oxide: beyond eNOS. J Pharmacol Sci. 2015;129:83\u201394. https:\/\/doi.org\/10.1016\/j.jphs.2015.09.002.","journal-title":"J Pharmacol Sci"},{"key":"1881_CR13","doi-asserted-by":"publisher","unstructured":"Aird WC. Endothelial cell heterogeneity. Cold Spring Harb Perspect Med. 2012;2. https:\/\/doi.org\/10.1101\/cshperspect.a006429.","DOI":"10.1101\/cshperspect.a006429"},{"key":"1881_CR14","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1007\/s40265-016-0642-8","volume":"76","author":"AC Cameron","year":"2016","unstructured":"Cameron AC, Lang NN, Touyz RM. Drug treatment of hypertension: focus on vascular health. Drugs. 2016;76:1529\u201350. https:\/\/doi.org\/10.1007\/s40265-016-0642-8.","journal-title":"Drugs"},{"key":"1881_CR15","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/nrneph.2015.162","volume":"11","author":"TJ Rabelink","year":"2015","unstructured":"Rabelink TJ, De Zeeuw D. The glycocalyx - Linking albuminuria with renal and cardiovascular disease. Nat Rev Nephrol. 2015;11:667\u201376. https:\/\/doi.org\/10.1038\/nrneph.2015.162.","journal-title":"Nat Rev Nephrol"},{"key":"1881_CR16","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.nano.2018.11.014","volume":"16","author":"M Maase","year":"2019","unstructured":"Maase M, Rygula A, Pacia MZ, Proniewski B, Mateuszuk L, Sternak M, et al. Combined Raman- and AFM-based detection of biochemical and nanomechanical features of endothelial dysfunction in aorta isolated from ApoE\/LDLR\u2212\/\u2212 mice. Nanomedicine. 2019;16:97\u2013105. https:\/\/doi.org\/10.1016\/j.nano.2018.11.014.","journal-title":"Nanomedicine"},{"key":"1881_CR17","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.bpj.2017.05.033","volume":"113","author":"AMW Bartosch","year":"2017","unstructured":"Bartosch AMW, Mathews R, Tarbell JM. Endothelial glycocalyx-mediated nitric oxide production in response to selective AFM pulling. Biophys J. 2017;113:101\u20138. https:\/\/doi.org\/10.1016\/j.bpj.2017.05.033.","journal-title":"Biophys J"},{"key":"1881_CR18","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/5584_2016_90\/FIGURES\/12","volume":"956","author":"D Konukoglu","year":"2016","unstructured":"Konukoglu D, Uzun H. Endothelial dysfunction and hypertension. Adv Exp Med Biol. 2016;956:511\u201340. https:\/\/doi.org\/10.1007\/5584_2016_90\/FIGURES\/12.","journal-title":"Adv Exp Med Biol"},{"key":"1881_CR19","doi-asserted-by":"publisher","unstructured":"Dri E, Lampas E, Lazaros G, Lazarou E, Theofilis P, Tsioufis C, et al. Inflammatory mediators of endothelial dysfunction. Life. 2023;13. https:\/\/doi.org\/10.3390\/LIFE13061420.","DOI":"10.3390\/LIFE13061420"},{"key":"1881_CR20","doi-asserted-by":"publisher","first-page":"754","DOI":"10.3389\/FIMMU.2018.00754","volume":"9","author":"NR Sproston","year":"2018","unstructured":"Sproston NR, Ashworth JJ. Role of C-reactive protein at sites of inflammation and infection. Front Immunol. 2018;9:754. https:\/\/doi.org\/10.3389\/FIMMU.2018.00754.","journal-title":"Front Immunol"},{"key":"1881_CR21","doi-asserted-by":"publisher","first-page":"153","DOI":"10.34297\/ajbsr.2022.15.002087","volume":"15","author":"N Tran","year":"2022","unstructured":"Tran N, Garcia T, Aniqa M, Ali S, Ally A, Nauli SM. Endothelial Nitric Oxide Synthase (eNOS) and the cardiovascular system: in physiology and in disease states. Am J Biomed Sci Res. 2022;15:153. https:\/\/doi.org\/10.34297\/ajbsr.2022.15.002087.","journal-title":"Am J Biomed Sci Res"},{"key":"1881_CR22","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/J.BCP.2009.04.029","volume":"78","author":"AH Sprague","year":"2009","unstructured":"Sprague AH, Khalil RA. Inflammatory cytokines in vascular dysfunction and vascular disease. Biochem Pharmacol. 2009;78:539\u201352. https:\/\/doi.org\/10.1016\/J.BCP.2009.04.029.","journal-title":"Biochem Pharmacol"},{"key":"1881_CR23","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.3390\/LIFE13061420","volume":"13","author":"E Dri","year":"2023","unstructured":"Dri E, Lampas E, Lazaros G, Lazarou E, Theofilis P, Tsioufis C, et al. Inflammatory mediators of endothelial dysfunction. Life. 2023;13:1420. https:\/\/doi.org\/10.3390\/LIFE13061420.","journal-title":"Life"},{"key":"1881_CR24","doi-asserted-by":"publisher","first-page":"7204","DOI":"10.18632\/ONCOTARGET.23208","volume":"9","author":"L Chen","year":"2018","unstructured":"Chen L, Deng H, Cui H, Fang J, Zuo Z, Deng J, et al. Inflammatory responses and inflammation-associated diseases in organs. Oncotarget. 2018;9:7204. https:\/\/doi.org\/10.18632\/ONCOTARGET.23208.","journal-title":"Oncotarget"},{"key":"1881_CR25","doi-asserted-by":"publisher","first-page":"7204","DOI":"10.18632\/ONCOTARGET.23208","volume":"9","author":"L Chen","year":"2017","unstructured":"Chen L, Deng H, Cui H, Fang J, Zuo Z, Deng J, et al. Inflammatory responses and inflammation-associated diseases in organs. Oncotarget. 2017;9:7204. https:\/\/doi.org\/10.18632\/ONCOTARGET.23208.","journal-title":"Oncotarget"},{"key":"1881_CR26","doi-asserted-by":"publisher","unstructured":"F\u00e9l\u00e9tou M. The endothelium. The endothelium: part 1: multiple functions of the endothelial cells\u2014focus on endothelium-derived vasoactive mediators. 2011;24:10\u20132. https:\/\/doi.org\/10.4199\/C00031ED1V01Y201105ISP019.","DOI":"10.4199\/C00031ED1V01Y201105ISP019"},{"key":"1881_CR27","doi-asserted-by":"publisher","first-page":"566410","DOI":"10.3389\/FPHYS.2020.566410","volume":"11","author":"J Ding","year":"2020","unstructured":"Ding J, Yu M, Jiang J, Luo Y, Zhang Q, Wang S, et al. Angiotensin II decreases endothelial nitric oxide synthase phosphorylation via AT1R Nox\/ROS\/PP2A pathway. Front Physiol. 2020;11:566410. https:\/\/doi.org\/10.3389\/FPHYS.2020.566410.","journal-title":"Front Physiol"},{"key":"1881_CR28","doi-asserted-by":"publisher","first-page":"281240","DOI":"10.4061\/2011\/281240","volume":"2011","author":"C Savoia","year":"2011","unstructured":"Savoia C, Sada L, Zezza L, Pucci L, Lauri FM, Befani A, et al. Vascular inflammation and endothelial dysfunction in experimental hypertension. Int J Hypertens. 2011;2011:281240. https:\/\/doi.org\/10.4061\/2011\/281240.","journal-title":"Int J Hypertens"},{"key":"1881_CR29","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.3390\/IJMS23031481","volume":"23","author":"H Kitaura","year":"2022","unstructured":"Kitaura H, Marahleh A, Ohori F, Noguchi T, Nara Y, Pramusita A, et al. Role of the interaction of tumor necrosis factor-\u03b1 and tumor necrosis factor receptors 1 and 2 in bone-related cells. Int J Mol Sci. 2022;23:1481. https:\/\/doi.org\/10.3390\/IJMS23031481.","journal-title":"Int J Mol Sci"},{"key":"1881_CR30","doi-asserted-by":"publisher","unstructured":"St. Paul A, Corbett CB, Okune R, Autieri M V. Angiotensin II, hypercholesterolemia, and vascular smooth muscle cells: a perfect trio for vascular pathology. Int J Mol Sci. 2020;21:1\u201316. https:\/\/doi.org\/10.3390\/IJMS21124525.","DOI":"10.3390\/IJMS21124525"},{"key":"1881_CR31","doi-asserted-by":"publisher","unstructured":"Gallo G, Volpe M, Savoia C. Endothelial dysfunction in hypertension: current concepts and clinical implications. Front Med (Lausanne). 2022;8. https:\/\/doi.org\/10.3389\/FMED.2021.798958.","DOI":"10.3389\/FMED.2021.798958"},{"key":"1881_CR32","doi-asserted-by":"publisher","unstructured":"Snezhkina A V., Kudryavtseva A V., Kardymon OL, Savvateeva M V., Melnikova N V., Krasnov GS, et al. ROS Generation and antioxidant defense systems in normal and malignant cells. Oxid Med Cell Longev. 2019;2019. https:\/\/doi.org\/10.1155\/2019\/6175804.","DOI":"10.1155\/2019\/6175804"},{"key":"1881_CR33","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/HR.2010.264","volume":"34","author":"R Rodrigo","year":"2011","unstructured":"Rodrigo R, Gonz\u00e1lez J, Paoletto F. The role of oxidative stress in the pathophysiology of hypertension. Hypertens Res. 2011;34:431\u201340. https:\/\/doi.org\/10.1038\/HR.2010.264.","journal-title":"Hypertens Res"},{"key":"1881_CR34","doi-asserted-by":"publisher","unstructured":"Zhang Z, Zhao L, Zhou X, Meng X, Zhou X. Role of inflammation, immunity, and oxidative stress in hypertension: new insights and potential therapeutic targets. Front Immunol. 2023;13. https:\/\/doi.org\/10.3389\/FIMMU.2022.1098725.","DOI":"10.3389\/FIMMU.2022.1098725"},{"key":"1881_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1423-0127-20-69\/TABLES\/1","volume":"20","author":"M Majzunova","year":"2013","unstructured":"Majzunova M, Dovinova I, Barancik M, Chan JYH. Redox signaling in pathophysiology of hypertension. J Biomed Sci. 2013;20:1\u201310. https:\/\/doi.org\/10.1186\/1423-0127-20-69\/TABLES\/1.","journal-title":"J Biomed Sci"},{"key":"1881_CR36","doi-asserted-by":"publisher","first-page":"L165","DOI":"10.1152\/AJPLUNG.00303.2020\/ASSET\/IMAGES\/LARGE\/AJ-ALUN210004F001.JPEG","volume":"320","author":"MJ McVey","year":"2021","unstructured":"McVey MJ, Steinberg BE, Goldenberg NM. Inflammasome activation in acute lung injury. Am J Physiol Lung Cell Mol Physiol. 2021;320:L165\u201378. https:\/\/doi.org\/10.1152\/AJPLUNG.00303.2020\/ASSET\/IMAGES\/LARGE\/AJ-ALUN210004F001.JPEG.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"7","key":"1881_CR37","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/nri.2016.58","volume":"16","author":"P Broz","year":"2016","unstructured":"Broz P, Dixit VM. Inflammasomes: mechanism of assembly, regulation and signalling. Nat Rev Immunol. 2016;16(7):407\u201320. https:\/\/doi.org\/10.1038\/nri.2016.58.","journal-title":"Nat Rev Immunol"},{"key":"1881_CR38","doi-asserted-by":"publisher","unstructured":"Brubaker SW, Brewer SM, Massis LM, Napier BA, Monack DM. A rapid caspase-11 response induced by IFN\u03b3 priming is independent of guanylate binding proteins. iScience. 2020;23. https:\/\/doi.org\/10.1016\/j.isci.2020.101612.","DOI":"10.1016\/j.isci.2020.101612"},{"key":"1881_CR39","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/S41573-023-00822-2","volume":"23","author":"L Vande Walle","year":"2024","unstructured":"Vande Walle L, Lamkanfi M. Drugging the NLRP3 inflammasome: from signalling mechanisms to therapeutic targets. Nat Rev Drug Discov. 2024;23:43\u201366. https:\/\/doi.org\/10.1038\/S41573-023-00822-2.","journal-title":"Nat Rev Drug Discov"},{"key":"1881_CR40","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/BS.AMPBS.2018.01.004","volume":"72","author":"RA Ramachandran","year":"2018","unstructured":"Ramachandran RA, Lupfer C, Zaki H. The inflammasome: regulation of nitric oxide and antimicrobial host defence. Adv Microb Physiol. 2018;72:65\u2013115. https:\/\/doi.org\/10.1016\/BS.AMPBS.2018.01.004.","journal-title":"Adv Microb Physiol"},{"key":"1881_CR41","doi-asserted-by":"publisher","first-page":"927061","DOI":"10.3389\/fcvm.2022.927061","volume":"9","author":"Y Zheng","year":"2022","unstructured":"Zheng Y, Xu L, Dong N, Li F. NLRP3 inflammasome: the rising star in cardiovascular diseases. Front Cardiovasc Med. 2022;9:927061.","journal-title":"Front Cardiovasc Med"},{"key":"1881_CR42","doi-asserted-by":"publisher","unstructured":"Pelegrin P. P2X7 receptor and the NLRP3 inflammasome: partners in crime. Biochem Pharmacol. 2021;187. https:\/\/doi.org\/10.1016\/J.BCP.2020.114385.","DOI":"10.1016\/J.BCP.2020.114385"},{"key":"1881_CR43","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1146\/ANNUREV-IMMUNOL-081022-021207\/CITE\/REFWORKS","volume":"41","author":"J Fu","year":"2023","unstructured":"Fu J, Wu H. Structural mechanisms of NLRP3 inflammasome assembly and activation. Annu Rev Immunol. 2023;41:301\u201316. https:\/\/doi.org\/10.1146\/ANNUREV-IMMUNOL-081022-021207\/CITE\/REFWORKS.","journal-title":"Annu Rev Immunol"},{"key":"1881_CR44","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1021\/JACSAU.3C00236\/ASSET\/IMAGES\/LARGE\/AU3C00236_0005.JPEG","volume":"3","author":"JR Lloyd","year":"2023","unstructured":"Lloyd JR, Biasutto A, D\u00fcrr KL, Jazayeri A, Hopper JTS, Oldham NJ. Mapping the binding interactions between human gasdermin D and human caspase-1 using carbene footprinting. JACS Au. 2023;3:2025\u201335. https:\/\/doi.org\/10.1021\/JACSAU.3C00236\/ASSET\/IMAGES\/LARGE\/AU3C00236_0005.JPEG.","journal-title":"JACS Au"},{"key":"1881_CR45","doi-asserted-by":"publisher","unstructured":"Sharma AK, Ismail N. Non-canonical inflammasome pathway: the role of cell death and inflammation in ehrlichiosis. Cells. 2023;12. https:\/\/doi.org\/10.3390\/CELLS12222597.","DOI":"10.3390\/CELLS12222597"},{"key":"1881_CR46","doi-asserted-by":"publisher","unstructured":"Unterberger S, Mullen L, Flint MS, Sacre S. Multiple TLRs elicit alternative NLRP3 inflammasome activation in primary human monocytes independent of RIPK1 kinase activity. Front Immunol. 2023;14. https:\/\/doi.org\/10.3389\/FIMMU.2023.1092799.","DOI":"10.3389\/FIMMU.2023.1092799"},{"key":"1881_CR47","doi-asserted-by":"publisher","first-page":"457869","DOI":"10.3389\/FPHAR.2019.01015\/BIBTEX","volume":"10","author":"M Orejudo","year":"2019","unstructured":"Orejudo M, Rodrigues-Diez RR, Rodrigues-Diez R, Garcia-Redondo A, Santos-S\u00e1nchez L, R\u00e1ndez-Garbayo J, et al. Interleukin 17A participates in renal inflammation associated to experimental and human hypertension. Front Pharmacol. 2019;10:457869. https:\/\/doi.org\/10.3389\/FPHAR.2019.01015\/BIBTEX.","journal-title":"Front Pharmacol"},{"key":"1881_CR48","doi-asserted-by":"publisher","first-page":"3959","DOI":"10.3390\/IJMS24043959\/S1","volume":"24","author":"J Youwakim","year":"2023","unstructured":"Youwakim J, Vallerand D, Girouard H. Neurovascular coupling in hypertension is impaired by IL-17A through oxidative stress. Int J Mol Sci. 2023;24:3959. https:\/\/doi.org\/10.3390\/IJMS24043959\/S1.","journal-title":"Int J Mol Sci"},{"key":"1881_CR49","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1093\/CVR\/CVAA257","volume":"117","author":"A Higaki","year":"2021","unstructured":"Higaki A, Mahmoud AUM, Paradis P, Schiffrin EL. Role of interleukin-23\/interleukin-17 axis in T-cell-mediated actions in hypertension. Cardiovasc Res. 2021;117:1274\u201383. https:\/\/doi.org\/10.1093\/CVR\/CVAA257.","journal-title":"Cardiovasc Res"},{"key":"1881_CR50","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.4049\/JIMMUNOL.1102527","volume":"188","author":"AC Liu","year":"2012","unstructured":"Liu AC, Lee M, McManus BM, Choy JC. Induction of endothelial nitric oxide synthase expression by IL-17 in human vascular endothelial cells: implications for vascular remodeling in transplant vasculopathy. J Immunol. 2012;188:1544\u201350. https:\/\/doi.org\/10.4049\/JIMMUNOL.1102527.","journal-title":"J Immunol"},{"key":"1881_CR51","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1080\/1744666X.2022.2045952","volume":"18","author":"FF Kreiner","year":"2022","unstructured":"Kreiner FF, Kraaijenhof JM, von Herrath M, Hovingh GKK, von Scholten BJ. Interleukin 6 in diabetes, chronic kidney disease, and cardiovascular disease: mechanisms and therapeutic perspectives. Expert Rev Clin Immunol. 2022;18:377\u201389. https:\/\/doi.org\/10.1080\/1744666X.2022.2045952.","journal-title":"Expert Rev Clin Immunol"},{"key":"1881_CR52","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1161\/HYPERTENSIONAHA.124.21712\/SUPPL_FILE\/HYP_HYPE-2023-21712_SUPP1.DOCX","volume":"81","author":"RR dos Passos","year":"2024","unstructured":"dos Passos RR, Santos CV, Priviero F, Briones AM, Tostes RC, Clinton Webb R, et al. Immunomodulatory activity of cytokines in hypertension: a vascular perspective. Hypertension. 2024;81:1411\u201323. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.124.21712\/SUPPL_FILE\/HYP_HYPE-2023-21712_SUPP1.DOCX.","journal-title":"Hypertension"},{"key":"1881_CR53","doi-asserted-by":"publisher","first-page":"585","DOI":"10.3390\/BIOM11040585","volume":"11","author":"AF Prado","year":"2021","unstructured":"Prado AF, Batista RIM, Tanus-Santos JE, Gerlach RF. Matrix Metalloproteinases and arterial hypertension: role of oxidative stress and nitric oxide in vascular functional and structural alterations. Biomolecules. 2021;11:585. https:\/\/doi.org\/10.3390\/BIOM11040585.","journal-title":"Biomolecules"},{"key":"1881_CR54","doi-asserted-by":"publisher","first-page":"1333170","DOI":"10.3389\/FIMMU.2024.1333170\/BIBTEX","volume":"15","author":"XM Hao","year":"2024","unstructured":"Hao XM, Liu Y, Hailaiti D, Gong Y, Zhang XD, Yue BN, et al. Mechanisms of inflammation modulation by different immune cells in hypertensive nephropathy. Front Immunol. 2024;15:1333170. https:\/\/doi.org\/10.3389\/FIMMU.2024.1333170\/BIBTEX.","journal-title":"Front Immunol"},{"key":"1881_CR55","doi-asserted-by":"publisher","first-page":"C1512","DOI":"10.1152\/AJPCELL.00272.2021","volume":"323","author":"BM Wynne","year":"2022","unstructured":"Wynne BM, Samson TK, Moyer HC, van Elst HJ, Moseley AS, Hecht G, et al. Interleukin 6 mediated activation of the mineralocorticoid receptor in the aldosterone-sensitive distal nephron. Am J Physiol Cell Physiol. 2022;323:C1512\u201323. https:\/\/doi.org\/10.1152\/AJPCELL.00272.2021.","journal-title":"Am J Physiol Cell Physiol"},{"key":"1881_CR56","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1111\/BPH.14481","volume":"176","author":"R Carnagarin","year":"2019","unstructured":"Carnagarin R, Matthews V, Zaldivia MTK, Peter K, Schlaich MP. The bidirectional interaction between the sympathetic nervous system and immune mechanisms in the pathogenesis of hypertension. Br J Pharmacol. 2019;176:1839\u201352. https:\/\/doi.org\/10.1111\/BPH.14481.","journal-title":"Br J Pharmacol"},{"key":"1881_CR57","doi-asserted-by":"publisher","first-page":"456901","DOI":"10.3389\/FCELL.2019.00091\/BIBTEX","volume":"7","author":"H Wajant","year":"2019","unstructured":"Wajant H, Siegmund D. TNFR1 and TNFR2 in the control of the life and death balance of macrophages. Front Cell Dev Biol. 2019;7:456901. https:\/\/doi.org\/10.3389\/FCELL.2019.00091\/BIBTEX.","journal-title":"Front Cell Dev Biol"},{"key":"1881_CR58","doi-asserted-by":"publisher","first-page":"3921074","DOI":"10.1155\/2020\/3921074","volume":"2020","author":"R Cai","year":"2020","unstructured":"Cai R, Hao Y, Liu YY, Huang L, Yao Y, Zhou MS. Tumor necrosis factor alpha deficiency improves endothelial function and cardiovascular injury in deoxycorticosterone acetate\/salt-hypertensive mice. Biomed Res Int. 2020;2020:3921074. https:\/\/doi.org\/10.1155\/2020\/3921074.","journal-title":"Biomed Res Int"},{"key":"1881_CR59","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1161\/CIRCRESAHA.116.303697","volume":"116","author":"WG McMaster","year":"2015","unstructured":"McMaster WG, Kirabo A, Madhur MS, Harrison DG. Inflammation, immunity, and hypertensive end-organ damage. Circ Res. 2015;116:1022\u201333. https:\/\/doi.org\/10.1161\/CIRCRESAHA.116.303697.","journal-title":"Circ Res"},{"key":"1881_CR60","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1096\/FJ.11-195198","volume":"26","author":"R Satou","year":"2012","unstructured":"Satou R, Miyata K, Gonzalez-Villalobos RA, Ingelfinger JR, Navar LG, Kobori H. Interferon-\u03b3 biphasically regulates angiotensinogen expression via a JAK-STAT pathway and suppressor of cytokine signaling 1 (SOCS1) in renal proximal tubular cells. FASEB J. 2012;26:1821\u201330. https:\/\/doi.org\/10.1096\/FJ.11-195198.","journal-title":"FASEB J"},{"key":"1881_CR61","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1093\/CVR\/CVY252","volume":"115","author":"SM Krishnan","year":"2019","unstructured":"Krishnan SM, Ling YH, Huuskes BM, Ferens DM, Saini N, Chan CT, et al. Pharmacological inhibition of the NLRP3 inflammasome reduces blood pressure, renal damage, and dysfunction in salt-sensitive hypertension. Cardiovasc Res. 2019;115:776\u201387. https:\/\/doi.org\/10.1093\/CVR\/CVY252.","journal-title":"Cardiovasc Res"},{"key":"1881_CR62","doi-asserted-by":"publisher","first-page":"5605","DOI":"10.1111\/JCMM.15220","volume":"24","author":"X Fan","year":"2020","unstructured":"Fan X, He L, Dai Q, He J, Chen X, Dai X, et al. Interleukin-1\u03b2 augments the angiogenesis of endothelial progenitor cells in an NF-\u03baB\/CXCR7-dependent manner. J Cell Mol Med. 2020;24:5605\u201314. https:\/\/doi.org\/10.1111\/JCMM.15220.","journal-title":"J Cell Mol Med"},{"key":"1881_CR63","doi-asserted-by":"publisher","first-page":"5589","DOI":"10.1111\/BPH.12876","volume":"171","author":"SM Krishnan","year":"2014","unstructured":"Krishnan SM, Sobey CG, Latz E, Mansell A, Drummond GR. IL-1\u03b2 and IL-18: inflammatory markers or mediators of hypertension? Br J Pharmacol. 2014;171:5589\u2013602. https:\/\/doi.org\/10.1111\/BPH.12876.","journal-title":"Br J Pharmacol"},{"key":"1881_CR64","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1161\/HYPERTENSIONAHA.123.22483\/ASSET\/DB3FC274-D276-4B6D-AC76-BD094977914E\/ASSETS\/GRAPHIC\/HYPERTENSIONAHA.123.22483.FIG03.JPG","volume":"81","author":"FJ Rios","year":"2024","unstructured":"Rios FJ, De Ciuceis C, Georgiopoulos G, Lazaridis A, Nosalski R, Pavlidis G, et al. Mechanisms of vascular inflammation and potential therapeutic targets: a position paper from the esh working group on small arteries. Hypertension. 2024;81:1218\u201332. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.123.22483\/ASSET\/DB3FC274-D276-4B6D-AC76-BD094977914E\/ASSETS\/GRAPHIC\/HYPERTENSIONAHA.123.22483.FIG03.JPG.","journal-title":"Hypertension"},{"key":"1881_CR65","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1124\/PR.114.010090","volume":"68","author":"S Goulopoulou","year":"2016","unstructured":"Goulopoulou S, McCarthy CG, Clinton WR. Toll-like receptors in the vascular system: sensing the dangers within. Pharmacol Rev. 2016;68:142\u201367. https:\/\/doi.org\/10.1124\/PR.114.010090.","journal-title":"Pharmacol Rev"},{"key":"1881_CR66","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1084\/JEM.20171773","volume":"215","author":"AE Norlander","year":"2018","unstructured":"Norlander AE, Madhur MS, Harrison DG. The immunology of hypertension. J Exp Med. 2018;215:21\u201333. https:\/\/doi.org\/10.1084\/JEM.20171773.","journal-title":"J Exp Med"},{"key":"1881_CR67","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1161\/CIRCULATIONAHA.116.027058","volume":"135","author":"A Caillon","year":"2017","unstructured":"Caillon A, Mian MOR, Fraulob-Aquino JC, Huo KG, Barhoumi T, Ouerd S, et al. \u03b3\u03b4 T cells mediate angiotensin II-induced hypertension and vascular injury. Circulation. 2017;135:2155\u201362. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.116.027058.","journal-title":"Circulation"},{"key":"1881_CR68","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1097\/HJH.0000000000000761","volume":"34","author":"MOR Mian","year":"2016","unstructured":"Mian MOR, Barhoumi T, Briet M, Paradis P, Schiffrin EL. Deficiency of T-regulatory cells exaggerates angiotensin II-induced microvascular injury by enhancing immune responses. J Hypertens. 2016;34:97\u2013108. https:\/\/doi.org\/10.1097\/HJH.0000000000000761.","journal-title":"J Hypertens"},{"key":"1881_CR69","doi-asserted-by":"publisher","first-page":"8536","DOI":"10.3390\/IJMS21228536","volume":"21","author":"PA Heidenreich","year":"2020","unstructured":"Heidenreich PA, Trogdon JG, Khavjou OA, Javed Butler M, Dracup K, Ezekowitz MD, et al. The role of neutrophils in hypertension. Int J Mol Sci. 2020;21:8536. https:\/\/doi.org\/10.3390\/IJMS21228536.","journal-title":"Int J Mol Sci"},{"key":"1881_CR70","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1007\/S11906-011-0207-X","volume":"13","author":"A Virdis","year":"2011","unstructured":"Virdis A, Ghiadoni L, Taddei S. Effects of antihypertensive treatment on endothelial function. Curr Hypertens Rep. 2011;13:276\u201381. https:\/\/doi.org\/10.1007\/S11906-011-0207-X.","journal-title":"Curr Hypertens Rep"},{"key":"1881_CR71","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/J.EJPHAR.2015.03.090","volume":"763","author":"BS Van Thiel","year":"2015","unstructured":"Van Thiel BS, Van Der Pluijm I, Te Riet L, Essers J, Danser AHJ. The renin-angiotensin system and its involvement in vascular disease. Eur J Pharmacol. 2015;763:3\u201314. https:\/\/doi.org\/10.1016\/J.EJPHAR.2015.03.090.","journal-title":"Eur J Pharmacol"},{"key":"1881_CR72","doi-asserted-by":"publisher","first-page":"497","DOI":"10.3904\/KJIM.2015.404","volume":"32","author":"HJ Kim","year":"2017","unstructured":"Kim HJ, Han SJ, Kim DJ, Jang HC, Lim S, Choi SH, et al. Effects of valsartan and amlodipine on oxidative stress in type 2 diabetic patients with hypertension: a randomized, multicenter study. Korean J Intern Med. 2017;32:497\u2013504. https:\/\/doi.org\/10.3904\/KJIM.2015.404.","journal-title":"Korean J Intern Med"},{"key":"1881_CR73","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1161\/01.HYP.37.3.943","volume":"37","author":"S Taddei","year":"2001","unstructured":"Taddei S, Virdis A, Ghiadoni L, Magagna A, Favilla S, Pompella A, et al. Restoration of nitric oxide availability after calcium antagonist treatment in essential hypertension. Hypertension. 2001;37:943\u20138. https:\/\/doi.org\/10.1161\/01.HYP.37.3.943.","journal-title":"Hypertension"},{"key":"1881_CR74","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1097\/00004872-199610000-00014","volume":"14","author":"EL Schiffrin","year":"1996","unstructured":"Schiffrin EL, Deng LY. Structure and function of resistance arteries of hypertensive patients treated with a beta-blocker or a calcium channel antagonist. J Hypertens. 1996;14:1247\u201355. https:\/\/doi.org\/10.1097\/00004872-199610000-00014.","journal-title":"J Hypertens"},{"key":"1881_CR75","doi-asserted-by":"publisher","unstructured":"Ritter JM. Nebivolol: endothelium-mediated vasodilating effect. J Cardiovasc Pharmacol. 2002;38. https:\/\/doi.org\/10.1097\/00005344-200112003-00003.","DOI":"10.1097\/00005344-200112003-00003"},{"key":"1881_CR76","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1097\/01.FJC.0000238593.67191.E2","volume":"48","author":"RP Mason","year":"2006","unstructured":"Mason RP, Kubant R, Jacob RF, Walter MF, Boychuk B, Malinski T. Effect of nebivolol on endothelial nitric oxide and peroxynitrite release in hypertensive animals: role of antioxidant activity. J Cardiovasc Pharmacol. 2006;48:862\u20139. https:\/\/doi.org\/10.1097\/01.FJC.0000238593.67191.E2.","journal-title":"J Cardiovasc Pharmacol"},{"key":"1881_CR77","doi-asserted-by":"publisher","first-page":"18014","DOI":"10.1038\/NRDP.2018.14","volume":"4","author":"S Oparil","year":"2018","unstructured":"Oparil S, Acelajado MC, Bakris GL, Berlowitz DR, C\u00edfkov\u00e1 R, Dominiczak AF, et al. Hypertension. Nat Rev Dis Primers. 2018;4:18014. https:\/\/doi.org\/10.1038\/NRDP.2018.14.","journal-title":"Nat Rev Dis Primers"},{"key":"1881_CR78","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1001\/JAMA.2016.19043","volume":"317","author":"MH Forouzanfar","year":"2017","unstructured":"Forouzanfar MH, Liu P, Roth GA, Ng M, Biryukov S, Marczak L, et al. Global burden of hypertension and systolic blood pressure of at least 110 to 115 mm Hg, 1990\u20132015. JAMA. 2017;317:165\u201382. https:\/\/doi.org\/10.1001\/JAMA.2016.19043.","journal-title":"JAMA"},{"key":"1881_CR79","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/S11906-010-0125-3","volume":"12","author":"CL Laffer","year":"2010","unstructured":"Laffer CL, Elijovich F. Inflammation and therapy for hypertension. Curr Hypertens Rep. 2010;12:233\u201342. https:\/\/doi.org\/10.1007\/S11906-010-0125-3.","journal-title":"Curr Hypertens Rep"},{"key":"1881_CR80","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1006\/jmcc.2000.1149","volume":"32","author":"AC Rosenkranz","year":"2000","unstructured":"Rosenkranz AC, Dusting GJ, Ritchie RH. Endothelial dysfunction limits the antihypertrophic action of Bradykinin in rat cardiomyocytes. J Mol Cell Cardiol. 2000;32:1119\u201326. https:\/\/doi.org\/10.1006\/jmcc.2000.1149.","journal-title":"J Mol Cell Cardiol"},{"key":"1881_CR81","doi-asserted-by":"publisher","unstructured":"Silva IVG, De Figueiredo RC, Rios DRA. Effect of different classes of antihypertensive drugs on endothelial function and inflammation. Int J Mol Sci. 2019;20. https:\/\/doi.org\/10.3390\/IJMS20143458.","DOI":"10.3390\/IJMS20143458"},{"key":"1881_CR82","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1161\/01.HYP.37.1.34","volume":"37","author":"V Brovkovych","year":"2001","unstructured":"Brovkovych V, Kalinowski L, Muller-Peddinghaus R, Malinski T. Synergistic antihypertensive effects of nifedipine on endothelium: concurrent release of NO and scavenging of superoxide. Hypertension. 2001;37:34\u20139. https:\/\/doi.org\/10.1161\/01.HYP.37.1.34.","journal-title":"Hypertension"},{"key":"1881_CR83","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1152\/PHYSREV.00018.2002","volume":"83","author":"E Perez-Reyes","year":"2003","unstructured":"Perez-Reyes E. Molecular physiology of low-voltage-activated t-type calcium channels. Physiol Rev. 2003;83:117\u201361. https:\/\/doi.org\/10.1152\/PHYSREV.00018.2002.","journal-title":"Physiol Rev"},{"key":"1881_CR84","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1161\/01.CIR.0000046488.52939.BF","volume":"107","author":"TF Luscher","year":"2003","unstructured":"Luscher TF, Azancot I, Balbi M, Bonnier JJRM, Desmet W, Diederich KW, et al. Effect of nifedipine and cerivastatin on coronary endothelial function in patients with coronary artery disease: the ENCORE I Study (Evaluation of Nifedipine and Cerivastatin On Recovery of coronary Endothelial function). Circulation. 2003;107:422\u20138. https:\/\/doi.org\/10.1161\/01.CIR.0000046488.52939.BF.","journal-title":"Circulation"},{"key":"1881_CR85","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1093\/EURHEARTJ\/EHP151","volume":"30","author":"TF L\u00fcscher","year":"2009","unstructured":"L\u00fcscher TF, Pieper M, Tendera M, Vrolix M, Rutsch W, Van Den Branden F, et al. A randomized placebo-controlled study on the effect of nifedipine on coronary endothelial function and plaque formation in patients with coronary artery disease: the ENCORE II study. Eur Heart J. 2009;30:1590\u20137. https:\/\/doi.org\/10.1093\/EURHEARTJ\/EHP151.","journal-title":"Eur Heart J"},{"key":"1881_CR86","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1093\/AJH\/HPT202","volume":"27","author":"RP Mason","year":"2014","unstructured":"Mason RP, Jacob RF, Corbalan JJ, Kaliszan R, Malinski T. Amlodipine increased endothelial nitric oxide and decreased nitroxidative stress disproportionately to blood pressure changes. Am J Hypertens. 2014;27:482. https:\/\/doi.org\/10.1093\/AJH\/HPT202.","journal-title":"Am J Hypertens"},{"key":"1881_CR87","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/J.AMJHYPER.2006.08.006","volume":"20","author":"W Palmas","year":"2007","unstructured":"Palmas W, Ma S, Psaty B, Goff DC, Darwin C, Barr RG. Antihypertensive medications and C-reactive protein in the multi-ethnic study of atherosclerosis. Am J Hypertens. 2007;20:233\u201341. https:\/\/doi.org\/10.1016\/J.AMJHYPER.2006.08.006.","journal-title":"Am J Hypertens"},{"key":"1881_CR88","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/S11845-017-1580-5","volume":"186","author":"V Buda","year":"2017","unstructured":"Buda V, Andor M, Cristescu C, Voicu M, Cochera F, Tuduce P, et al. The effect of candesartan on pentraxin-3 plasma levels as marker of endothelial dysfunction in patients with essential arterial hypertension. Ir J Med Sci. 2017;186:621\u20139. https:\/\/doi.org\/10.1007\/S11845-017-1580-5.","journal-title":"Ir J Med Sci"},{"key":"1881_CR89","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1161\/HYPERTENSIONAHA.108.119404","volume":"52","author":"JW Eriksson","year":"2008","unstructured":"Eriksson JW, Jansson PA, Carlberg B, H\u00e4gg A, Kurland L, Svensson MK, et al. Hydrochlorothiazide, but not Candesartan, aggravates insulin resistance and causes visceral and hepatic fat accumulation: the mechanisms for the diabetes preventing effect of Candesartan (MEDICA) Study. Hypertension. 2008;52:1030\u20137. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.108.119404.","journal-title":"Hypertension"},{"key":"1881_CR90","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1161\/01.HYP.0000226046.58883.32","volume":"48","author":"PM Ridker","year":"2006","unstructured":"Ridker PM, Danielson E, Rifai N, Glynn RJ. Valsartan, blood pressure reduction, and C-reactive protein: primary report of the Val-MARC trial. Hypertension. 2006;48:73\u20139. https:\/\/doi.org\/10.1161\/01.HYP.0000226046.58883.32.","journal-title":"Hypertension"},{"key":"1881_CR91","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMOA1707914","volume":"377","author":"PM Ridker","year":"2017","unstructured":"Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377:1119\u201331. https:\/\/doi.org\/10.1056\/NEJMOA1707914.","journal-title":"N Engl J Med"},{"key":"1881_CR92","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/S41569-018-0064-2","volume":"15","author":"L Ferrucci","year":"2018","unstructured":"Ferrucci L, Fabbri E. Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty. Nat Rev Cardiol. 2018;15:505. https:\/\/doi.org\/10.1038\/S41569-018-0064-2.","journal-title":"Nat Rev Cardiol"},{"key":"1881_CR93","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1001\/JAMACARDIO.2018.4566","volume":"4","author":"TSG Sehested","year":"2019","unstructured":"Sehested TSG, Bjerre J, Ku S, Chang A, Jahansouz A, Owens DK, et al. Cost-effectiveness of canakinumab for prevention of recurrent cardiovascular events. JAMA Cardiol. 2019;4:128\u201335. https:\/\/doi.org\/10.1001\/JAMACARDIO.2018.4566.","journal-title":"JAMA Cardiol"},{"key":"1881_CR94","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1016\/J.JACC.2021.02.049","volume":"77","author":"K Broch","year":"2021","unstructured":"Broch K, Anstensrud AK, Woxholt S, Sharma K, T\u00f8llefsen IM, Bendz B, et al. Randomized trial of interleukin-6 receptor inhibition in patients with acute ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2021;77:1845\u201355. https:\/\/doi.org\/10.1016\/J.JACC.2021.02.049.","journal-title":"J Am Coll Cardiol"},{"key":"1881_CR95","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/J.CYTO.2014.12.024","volume":"74","author":"JA Fontes","year":"2015","unstructured":"Fontes JA, Rose NR, \u010cih\u00e1kov\u00e1 D. The varying faces of IL-6: from cardiac protection to cardiac failure. Cytokine. 2015;74:62\u20138. https:\/\/doi.org\/10.1016\/J.CYTO.2014.12.024.","journal-title":"Cytokine"},{"key":"1881_CR96","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1016\/S0140-6736(21)00520-1","volume":"397","author":"PM Ridker","year":"2021","unstructured":"Ridker PM, Devalaraja M, Baeres FMM, Engelmann MDM, Hovingh GK, Ivkovic M, et al. IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2021;397:2060\u20139. https:\/\/doi.org\/10.1016\/S0140-6736(21)00520-1.","journal-title":"Lancet"},{"key":"1881_CR97","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/JCM9103267","volume":"9","author":"F Rolski","year":"2020","unstructured":"Rolski F, B\u0142yszczuk P. Complexity of TNF-\u03b1 signaling in heart disease. J Clin Med. 2020;9:1\u201325. https:\/\/doi.org\/10.3390\/JCM9103267.","journal-title":"J Clin Med"},{"key":"1881_CR98","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1161\/01.CIR.0000124490.27666.B2","volume":"109","author":"DL Mann","year":"2004","unstructured":"Mann DL, McMurray JJV, Packer M, Swedberg K, Borer JS, Colucci WS, et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation. 2004;109:1594\u2013602. https:\/\/doi.org\/10.1161\/01.CIR.0000124490.27666.B2.","journal-title":"Circulation"},{"key":"1881_CR99","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.1002\/ART.22809","volume":"56","author":"WG Dixon","year":"2007","unstructured":"Dixon WG, Watson KD, Lunt M, Hyrich KL, Silman AJ, Symmons DPM, et al. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 2007;56:2905\u201312. https:\/\/doi.org\/10.1002\/ART.22809.","journal-title":"Arthritis Rheum"},{"key":"1881_CR100","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1038\/NRCARDIO.2009.57","volume":"6","author":"GE McKellar","year":"2009","unstructured":"McKellar GE, McCarey DW, Sattar N, McInnes IB. Role for TNF in atherosclerosis? Lessons from autoimmune disease. Nat Rev Cardiol. 2009;6:410\u20137. https:\/\/doi.org\/10.1038\/NRCARDIO.2009.57.","journal-title":"Nat Rev Cardiol"},{"key":"1881_CR101","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1038\/S41401-021-00835-W","volume":"43","author":"F-s Zhang","year":"2022","unstructured":"Zhang F-s, He Q-z, Qin CH, Little PJ, Weng J-p, Xu S-w. Therapeutic potential of colchicine in cardiovascular medicine: a pharmacological review. Acta Pharmacol Sin. 2022;43:2173. https:\/\/doi.org\/10.1038\/S41401-021-00835-W.","journal-title":"Acta Pharmacol Sin"},{"key":"1881_CR102","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/S0306-9877(98)90031-7","volume":"51","author":"E Ben-Chetrit","year":"1998","unstructured":"Ben-Chetrit E, Levy M. Does the lack of the P-glycoprotein efflux pump in neutrophils explain the efficacy of colchicine in familial Mediterranean fever and other inflammatory diseases? Med Hypotheses. 1998;51:377\u201380. https:\/\/doi.org\/10.1016\/S0306-9877(98)90031-7.","journal-title":"Med Hypotheses"},{"key":"1881_CR103","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1161\/CIRCULATIONAHA.121.056171","volume":"145","author":"SG Deftereos","year":"2022","unstructured":"Deftereos SG, Beerkens FJ, Shah B, Giannopoulos G, Vrachatis DA, Giotaki SG, et al. Colchicine in cardiovascular disease: in-depth review. Circulation. 2022;145:61\u201378. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.121.056171.","journal-title":"Circulation"},{"key":"1881_CR104","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1161\/CIRCULATIONAHA.120.050771","volume":"142","author":"DC Tong","year":"2020","unstructured":"Tong DC, Quinn S, Nasis A, Hiew C, Roberts-Thomson P, Adams H, et al. Colchicine in patients with acute coronary syndrome: the Australian COPS randomized clinical trial. Circulation. 2020;142:1890\u2013900. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.050771.","journal-title":"Circulation"},{"key":"1881_CR105","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1161\/CIRCULATIONAHA.121.056177","volume":"144","author":"N Mewton","year":"2021","unstructured":"Mewton N, Roubille F, Bresson D, Prieur C, Bouleti C, Bochaton T, et al. Effect of colchicine on myocardial injury in acute myocardial infarction. Circulation. 2021;144:859\u201369. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.121.056177.","journal-title":"Circulation"},{"key":"1881_CR106","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1093\/EHJQCCO\/QCAA045","volume":"7","author":"M Samuel","year":"2021","unstructured":"Samuel M, Tardif JC, Khairy P, Roubille F, Waters DD, Gr\u00e9goire JC, et al. Cost-effectiveness of low-dose colchicine after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT). Eur Heart J Qual Care Clin Outcomes. 2021;7:486\u201395. https:\/\/doi.org\/10.1093\/EHJQCCO\/QCAA045.","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"1881_CR107","doi-asserted-by":"publisher","unstructured":"Daussy CF, Monard SC, Guy C, Mu\u00f1oz-Gonz\u00e1lez S, Chazal M, Anthonsen MW, et al. The inflammasome components NLRP3 and ASC act in concert with IRGM to rearrange the golgi apparatus during hepatitis C virus infection. J Virol. 2021;95. https:\/\/doi.org\/10.1128\/JVI.00826-20.","DOI":"10.1128\/JVI.00826-20"},{"key":"1881_CR108","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/J.IMMUNI.2016.01.012","volume":"44","author":"MM Gaidt","year":"2016","unstructured":"Gaidt MM, Ebert TS, Chauhan D, Schmidt T, Schmid-Burgk JL, Rapino F, et al. Human monocytes engage an alternative inflammasome pathway. Immunity. 2016;44:833\u201346. https:\/\/doi.org\/10.1016\/J.IMMUNI.2016.01.012.","journal-title":"Immunity"},{"key":"1881_CR109","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/J.PHARMTHERA.2010.05.002","volume":"127","author":"P Kleinbongard","year":"2010","unstructured":"Kleinbongard P, Heusch G, Schulz R. TNFalpha in atherosclerosis, myocardial ischemia\/reperfusion and heart failure. Pharmacol Ther. 2010;127:295\u2013314. https:\/\/doi.org\/10.1016\/J.PHARMTHERA.2010.05.002.","journal-title":"Pharmacol Ther"},{"key":"1881_CR110","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1159\/000028039","volume":"66","author":"V Lindner","year":"1998","unstructured":"Lindner V. The NF-\u03baB and I\u03baB system in injured arteries. Pathobiology. 1998;66:311\u201320. https:\/\/doi.org\/10.1159\/000028039.","journal-title":"Pathobiology"},{"key":"1881_CR111","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/NRI2691","volume":"10","author":"JE Sims","year":"2010","unstructured":"Sims JE, Smith DE. The IL-1 family: regulators of immunity. Nat Rev Immunol. 2010;10:89\u2013102. https:\/\/doi.org\/10.1038\/NRI2691.","journal-title":"Nat Rev Immunol"},{"key":"1881_CR112","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/J.PHARMTHERA.2015.12.005","volume":"158","author":"Y Wang","year":"2016","unstructured":"Wang Y, Song E, Bai B, Vanhoutte PM. Toll-like receptors mediating vascular malfunction: lessons from receptor subtypes. Pharmacol Ther. 2016;158:91\u2013100. https:\/\/doi.org\/10.1016\/J.PHARMTHERA.2015.12.005.","journal-title":"Pharmacol Ther"},{"key":"1881_CR113","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/S41578-022-00426-Z","volume":"7","author":"Z Tu","year":"2022","unstructured":"Tu Z, Zhong Y, Hu H, Shao D, Haag R, Schirner M, et al. Design of therapeutic biomaterials to control inflammation. Nat Rev Mater. 2022;7:557. https:\/\/doi.org\/10.1038\/S41578-022-00426-Z.","journal-title":"Nat Rev Mater"},{"key":"1881_CR114","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.3390\/MOLECULES27041372","volume":"27","author":"P Liu","year":"2022","unstructured":"Liu P, Chen G, Zhang J. A review of liposomes as a drug delivery system: current status of approved products, regulatory environments, and future perspectives. Molecules. 2022;27:1372. https:\/\/doi.org\/10.3390\/MOLECULES27041372.","journal-title":"Molecules"},{"key":"1881_CR115","doi-asserted-by":"publisher","first-page":"104098","DOI":"10.1016\/J.DRUDIS.2024.104098","volume":"29","author":"AA Assiri","year":"2024","unstructured":"Assiri AA, Glover K, Mishra D, Waite D, Vora LK, Thakur RRS. Block copolymer micelles as ocular drug delivery systems. Drug Discov Today. 2024;29:104098. https:\/\/doi.org\/10.1016\/J.DRUDIS.2024.104098.","journal-title":"Drug Discov Today"},{"key":"1881_CR116","doi-asserted-by":"publisher","first-page":"3731","DOI":"10.3390\/MOLECULES25163731","volume":"25","author":"A Zielinska","year":"2020","unstructured":"Zielinska A, Carreir\u00f3 F, Oliveira AM, Neves A, Pires B, Nagasamy Venkatesh D, et al. Polymeric nanoparticles: production, characterization, toxicology and ecotoxicology. Molecules. 2020;25:3731. https:\/\/doi.org\/10.3390\/MOLECULES25163731.","journal-title":"Molecules"},{"key":"1881_CR117","doi-asserted-by":"publisher","first-page":"8844030","DOI":"10.1155\/2021\/8844030","volume":"2021","author":"P Mittal","year":"2021","unstructured":"Mittal P, Saharan A, Verma R, Altalbawy FMA, Alfaidi MA, Batiha GES, et al. Dendrimers: a new race of pharmaceutical nanocarriers. Biomed Res Int. 2021;2021:8844030. https:\/\/doi.org\/10.1155\/2021\/8844030.","journal-title":"Biomed Res Int"},{"key":"1881_CR118","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12951-023-02246-X","volume":"22","author":"Q Li","year":"2024","unstructured":"Li Q, Lin L, Zhang C, Zhang H, Ma Y, Qian H, et al. The progression of inorganic nanoparticles and natural products for inflammatory bowel disease. J Nanobiotechnol. 2024;22:1\u201328. https:\/\/doi.org\/10.1186\/S12951-023-02246-X.","journal-title":"J Nanobiotechnol"},{"key":"1881_CR119","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1021\/ACSMATERIALSAU.3C00032\/ASSET\/IMAGES\/LARGE\/MG3C00032_0004.JPEG","volume":"3","author":"M Mehta","year":"2023","unstructured":"Mehta M, Bui TA, Yang X, Aksoy Y, Goldys EM, Deng W. Lipid-based nanoparticles for drug\/gene delivery: an overview of the production techniques and difficulties encountered in their industrial development. ACS Materials Au. 2023;3:600\u201319. https:\/\/doi.org\/10.1021\/ACSMATERIALSAU.3C00032\/ASSET\/IMAGES\/LARGE\/MG3C00032_0004.JPEG.","journal-title":"ACS Materials Au"},{"key":"1881_CR120","doi-asserted-by":"publisher","first-page":"1155622","DOI":"10.3389\/FMICB.2023.1155622","volume":"14","author":"KA Altammar","year":"2023","unstructured":"Altammar KA. A review on nanoparticles: characteristics, synthesis, applications, and challenges. Front Microbiol. 2023;14:1155622. https:\/\/doi.org\/10.3389\/FMICB.2023.1155622.","journal-title":"Front Microbiol"},{"key":"1881_CR121","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/S13346-024-01710-X","volume":"2024","author":"SA Vahab","year":"2024","unstructured":"Vahab SA, V VK, Kumar VS. Exosome-based drug delivery systems for enhanced neurological therapeutics. Drug Deliv Transl Res. 2024;2024:1\u201318. https:\/\/doi.org\/10.1007\/S13346-024-01710-X.","journal-title":"Drug Deliv Transl Res"},{"key":"1881_CR122","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/978-3-0348-7276-8_15","volume":"46","author":"WA Muller","year":"1995","unstructured":"Muller WA. The use of anti-PECAM reagents in the control of inflammation. Agents Actions Suppl. 1995;46:147\u201357. https:\/\/doi.org\/10.1007\/978-3-0348-7276-8_15.","journal-title":"Agents Actions Suppl"},{"key":"1881_CR123","doi-asserted-by":"publisher","first-page":"3550","DOI":"10.4049\/JIMMUNOL.156.9.3550","volume":"156","author":"T Murohara","year":"1996","unstructured":"Murohara T, Delyani JA, Albelda SM, Lefer AM. Blockade of platelet endothelial cell adhesion molecule-1 protects against myocardial ischemia and reperfusion injury in cats. J Immunol. 1996;156:3550\u20137. https:\/\/doi.org\/10.4049\/JIMMUNOL.156.9.3550.","journal-title":"J Immunol"},{"key":"1881_CR124","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1124\/JPET.109.156877","volume":"331","author":"VV Shuvaev","year":"2009","unstructured":"Shuvaev VV, Christofidou-Solomidou M, Bhora F, Laude K, Cai H, Dikalov S, et al. Targeted detoxification of selected reactive oxygen species in the vascular endothelium. J Pharmacol Exp Ther. 2009;331:404\u201311. https:\/\/doi.org\/10.1124\/JPET.109.156877.","journal-title":"J Pharmacol Exp Ther"},{"key":"1881_CR125","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1002\/CMMI.1536","volume":"8","author":"LH Deddens","year":"2013","unstructured":"Deddens LH, van Tilborg GAF, van der Toorn A, de Vries HE, Dijkhuizen RM. PECAM-1-targeted micron-sized particles of iron oxide as mri contrast agent for detection of vascular remodeling after cerebral ischemia. Contrast Media Mol Imaging. 2013;8:393\u2013401. https:\/\/doi.org\/10.1002\/CMMI.1536.","journal-title":"Contrast Media Mol Imaging"},{"key":"1881_CR126","doi-asserted-by":"publisher","first-page":"64839","DOI":"10.3389\/FPHAR.2013.00127\/BIBTEX","volume":"4","author":"S Hua","year":"2013","unstructured":"Hua S. Targeting sites of inflammation: intercellular adhesion molecule-1 as a target for novel inflammatory therapies. Front Pharmacol. 2013;4:64839. https:\/\/doi.org\/10.3389\/FPHAR.2013.00127\/BIBTEX.","journal-title":"Front Pharmacol"},{"key":"1881_CR127","doi-asserted-by":"publisher","first-page":"2362","DOI":"10.1172\/JCI118679","volume":"97","author":"T Kumasaka","year":"1996","unstructured":"Kumasaka T, Quinlan WM, Doyle NA, Condon TP, Sligh J, Takei F, et al. Role of the intercellular adhesion molecule-1(ICAM-1) in endotoxin-induced pneumonia evaluated using ICAM-1 antisense oligonucleotides, anti-ICAM-1 monoclonal antibodies, and ICAM-1 mutant mice. J Clin Invest. 1996;97:2362\u20139. https:\/\/doi.org\/10.1172\/JCI118679.","journal-title":"J Clin Invest"},{"key":"1881_CR128","doi-asserted-by":"publisher","first-page":"4609","DOI":"10.4049\/JIMMUNOL.157.10.4609","volume":"157","author":"CM Doerschuk","year":"1996","unstructured":"Doerschuk CM, Quinlan WM, Doyle NA, Bullard DC, Vestweber D, Jones ML, et al. The role of P-selectin and ICAM-1 in acute lung injury as determined using blocking antibodies and mutant mice. J Immunol. 1996;157:4609\u201314. https:\/\/doi.org\/10.4049\/JIMMUNOL.157.10.4609.","journal-title":"J Immunol"},{"key":"1881_CR129","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/J.PHYSA.2017.10.001","volume":"492","author":"SN Li","year":"2018","unstructured":"Li SN, Cao BY. Memory behaviors of entropy production rates in heat conduction. Physica A. 2018;492:105\u201312. https:\/\/doi.org\/10.1016\/J.PHYSA.2017.10.001.","journal-title":"Physica A"},{"key":"1881_CR130","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/J.JCONREL.2019.03.008","volume":"301","author":"OA Marcos-Contreras","year":"2019","unstructured":"Marcos-Contreras OA, Brenner JS, Kiseleva RY, Zuluaga-Ramirez V, Greineder CF, Villa CH, et al. Combining vascular targeting and the local first pass provides 100-fold higher uptake of ICAM-1-targeted vs untargeted nanocarriers in the inflamed brain. J Control Release. 2019;301:54\u201361. https:\/\/doi.org\/10.1016\/J.JCONREL.2019.03.008.","journal-title":"J Control Release"},{"key":"1881_CR131","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1093\/CVR\/CVAD130","volume":"119","author":"JR Pickett","year":"2023","unstructured":"Pickett JR, Wu Y, Zacchi LF, Ta HT. Targeting endothelial vascular cell adhesion molecule-1 in atherosclerosis: drug discovery and development of vascular cell adhesion molecule-1\u2013directed novel therapeutics. Cardiovasc Res. 2023;119:2278. https:\/\/doi.org\/10.1093\/CVR\/CVAD130.","journal-title":"Cardiovasc Res"},{"key":"1881_CR132","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/SJ.JCBFM.9600198\/ASSET\/IMAGES\/LARGE\/10.1038_SJ.JCBFM.9600198-FIG7.JPEG","volume":"26","author":"C Justicia","year":"2006","unstructured":"Justicia C, Mart\u00edn A, Rojas S, Gironella M, Cervera \u00c1, Pan\u00e9s J, et al. Anti-VCAM-1 antibodies did not protect against ischemic damage either in rats or in mice. J Cereb Blood Flow Metab. 2006;26:421\u201332. https:\/\/doi.org\/10.1038\/SJ.JCBFM.9600198\/ASSET\/IMAGES\/LARGE\/10.1038_SJ.JCBFM.9600198-FIG7.JPEG.","journal-title":"J Cereb Blood Flow Metab"},{"key":"1881_CR133","doi-asserted-by":"publisher","first-page":"e0196976","DOI":"10.1371\/JOURNAL.PONE.0196976","volume":"13","author":"R Li","year":"2018","unstructured":"Li R, Kowalski PS, Morselt HWM, Schepel I, Jongman RM, Aslan A, et al. Endothelium-targeted delivery of dexamethasone by anti-VCAM-1 SAINT-O-Somes in mouse endotoxemia. PLoS ONE. 2018;13:e0196976. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0196976.","journal-title":"PLoS ONE"},{"key":"1881_CR134","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1161\/STROKEAHA.111.000544","volume":"44","author":"M Gauberti","year":"2013","unstructured":"Gauberti M, Montagne A, Marcos-Contreras OA, Le B\u00e9hot A, Maubert E, Vivien D. Ultra-sensitive molecular MRI of vascular cell adhesion molecule-1 reveals a dynamic inflammatory penumbra after strokes. Stroke. 2013;44:1988\u201396. https:\/\/doi.org\/10.1161\/STROKEAHA.111.000544.","journal-title":"Stroke"},{"key":"1881_CR135","doi-asserted-by":"publisher","first-page":"3405","DOI":"10.1073\/PNAS.1912012117\/-\/DCSUPPLEMENTAL","volume":"117","author":"OA Marcos-Contreras","year":"2020","unstructured":"Marcos-Contreras OA, Greineder CF, Kiseleva RY, Parhiz H, Walsh LR, Zuluaga-Ramirez V, et al. Selective targeting of nanomedicine to inflamed cerebral vasculature to enhance the blood\u2013brain barrier. Proc Natl Acad Sci U S A. 2020;117:3405\u201314. https:\/\/doi.org\/10.1073\/PNAS.1912012117\/-\/DCSUPPLEMENTAL.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1881_CR136","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/0304-4157(94)90006-X","volume":"1197","author":"JK Welply","year":"1994","unstructured":"Welply JK, Keene JL, Schmuke JJ, Howard SC. Selectins as potential targets of therapeutic intervention in inflammatory diseases. Biochim Biophys Acta (BBA) Rev Biomembr. 1994;1197:215\u201326. https:\/\/doi.org\/10.1016\/0304-4157(94)90006-X.","journal-title":"Biochim Biophys Acta (BBA) Rev Biomembr"},{"key":"1881_CR137","doi-asserted-by":"publisher","unstructured":"Liu Y, Yang B, Zhao X, Xi M, Yin Z. E-selectin-binding peptide-modified bovine serum albumin nanoparticles for the treatment of acute lung injury. AAPS PharmSciTech. 2019;20. https:\/\/doi.org\/10.1208\/S12249-019-1403-2.","DOI":"10.1208\/S12249-019-1403-2"},{"key":"1881_CR138","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/S0022-510X(98)00262-7","volume":"161","author":"AV Goussev","year":"1998","unstructured":"Goussev AV, Zhang Z, Anderson DC, Chopp M. P-selectin antibody reduces hemorrhage and infarct volume resulting from MCA occlusion in the rat. J Neurol Sci. 1998;161:16\u201322. https:\/\/doi.org\/10.1016\/S0022-510X(98)00262-7.","journal-title":"J Neurol Sci"},{"key":"1881_CR139","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/S00415-005-0996-4\/METRICS","volume":"253","author":"J Lehmberg","year":"2006","unstructured":"Lehmberg J, Beck J, Baethmann A, Uhl E. Effect of P-selectin inhibition on leukocyte-endothelium interaction and survival after global cerebral ischemia. J Neurol. 2006;253:357\u201363. https:\/\/doi.org\/10.1007\/S00415-005-0996-4\/METRICS.","journal-title":"J Neurol"},{"key":"1881_CR140","doi-asserted-by":"publisher","unstructured":"Pang X, He X, Qiu Z, Zhang H, Xie R, Liu Z, et al. Targeting integrin pathways: mechanisms and advances in therapy. Signal Transduct Target Ther. 2023;8. https:\/\/doi.org\/10.1038\/S41392-022-01259-6.","DOI":"10.1038\/S41392-022-01259-6"},{"key":"1881_CR141","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/0092-8674(81)90308-1","volume":"26","author":"MD Pierschbacher","year":"1981","unstructured":"Pierschbacher MD, Hayman EG, Ruoslahti E. Location of the cell-attachment site in fibronectin with monoclonal antibodies and proteolytic fragments of the molecule. Cell. 1981;26:259\u201367. https:\/\/doi.org\/10.1016\/0092-8674(81)90308-1.","journal-title":"Cell"},{"key":"1881_CR142","doi-asserted-by":"publisher","first-page":"102351","DOI":"10.1016\/J.NANO.2020.102351","volume":"33","author":"V Pooladanda","year":"2021","unstructured":"Pooladanda V, Thatikonda S, Sunnapu O, Tiwary S, Vemula PK, Talluri MVNK, et al. iRGD conjugated nimbolide liposomes protect against endotoxin induced acute respiratory distress syndrome. Nanomedicine. 2021;33:102351. https:\/\/doi.org\/10.1016\/J.NANO.2020.102351.","journal-title":"Nanomedicine"},{"key":"1881_CR143","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/J.BIOMATERIALS.2017.10.012","volume":"150","author":"T Tian","year":"2018","unstructured":"Tian T, Zhang HX, He CP, Fan S, Zhu YL, Qi C, et al. Surface functionalized exosomes as targeted drug delivery vehicles for cerebral ischemia therapy. Biomaterials. 2018;150:137\u201349. https:\/\/doi.org\/10.1016\/J.BIOMATERIALS.2017.10.012.","journal-title":"Biomaterials"},{"key":"1881_CR144","doi-asserted-by":"publisher","unstructured":"Zhu L, Ding Z, Li X, Wei H, Chen Y. Research progress of radiolabeled Asn-Gly-Arg (NGR) peptides for imaging and therapy. Mol Imaging. 2020;19. https:\/\/doi.org\/10.1177\/1536012120934957.","DOI":"10.1177\/1536012120934957"},{"key":"1881_CR145","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1182\/BLOOD-2008-04-150862","volume":"112","author":"A Corti","year":"2008","unstructured":"Corti A, Curnis F, Arap W, Pasqualini R. The neovasculature homing motif NGR: more than meets the eye. Blood. 2008;112:2628. https:\/\/doi.org\/10.1182\/BLOOD-2008-04-150862.","journal-title":"Blood"},{"key":"1881_CR146","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1089\/LRB.2008.1011","volume":"6","author":"B Garmy-Susini","year":"2008","unstructured":"Garmy-Susini B, Varner JA. Roles of integrins in tumor angiogenesis and lymphangiogenesis. Lymphat Res Biol. 2008;6:155. https:\/\/doi.org\/10.1089\/LRB.2008.1011.","journal-title":"Lymphat Res Biol"},{"key":"1881_CR147","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1517\/13543776.2013.818133","volume":"23","author":"TG Kapp","year":"2013","unstructured":"Kapp TG, Rechenmacher F, Sobahi TR, Kessler H. Integrin modulators: a patent review. Expert Opin Ther Pat. 2013;23:1273\u201395. https:\/\/doi.org\/10.1517\/13543776.2013.818133.","journal-title":"Expert Opin Ther Pat"},{"key":"1881_CR148","doi-asserted-by":"publisher","first-page":"3803","DOI":"10.2147\/IJN.S33541","volume":"7","author":"Z Chen","year":"2012","unstructured":"Chen Z, Deng J, Zhao Y, Tao T. Cyclic RGD peptide-modified liposomal drug delivery system: enhanced cellular uptake in vitro and improved pharmacokinetics in rats. Int J Nanomed. 2012;7:3803\u201311. https:\/\/doi.org\/10.2147\/IJN.S33541.","journal-title":"Int J Nanomed"},{"key":"1881_CR149","doi-asserted-by":"publisher","unstructured":"Milewska S, Sadowska A, Stefaniuk N, Misztalewska-Turkowicz I, Wilczewska AZ, Car H, Niemirowicz-Laskowska K. Tumor-homing peptides as crucial component of magnetic-based delivery systems: Recent developments and pharmacoeconomical perspective. Int J Mol Sci. 2024;25(11):6219. https:\/\/doi.org\/10.3390\/ijms25116219","DOI":"10.3390\/ijms25116219"},{"key":"1881_CR150","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.ijpharm.2013.10.018","volume":"458","author":"M Amin","year":"2013","unstructured":"Amin M, Badiee A, Jaafari MR. Improvement of pharmacokinetic and antitumor activity of PEGylated liposomal doxorubicin by targeting with N-methylated cyclic RGD peptide in mice bearing C-26 colon carcinomas. Int J Pharm. 2013;458:324\u201333. https:\/\/doi.org\/10.1016\/j.ijpharm.2013.10.018.","journal-title":"Int J Pharm"},{"issue":"5990","key":"1881_CR151","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/312162a0","volume":"312","author":"WA Jefferies","year":"1984","unstructured":"Jefferies WA, Brandon MR, Hunt SV, Williams AF, Gatter KC, Mason DY. Transferrin receptor on endothelium of brain capillaries. Nature. 1984;312(5990):162\u20133. https:\/\/doi.org\/10.1038\/312162a0.","journal-title":"Nature"},{"key":"1881_CR152","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/J.NEUROSCIENCE.2016.04.033","volume":"329","author":"J Hu","year":"2016","unstructured":"Hu J, Al-Waili D, Hassan A, Fan GC, Xin M, Hao J. Inhibition of cerebral vascular inflammation by brain endothelium-targeted oligodeoxynucleotide complex. Neuroscience. 2016;329:30\u201342. https:\/\/doi.org\/10.1016\/J.NEUROSCIENCE.2016.04.033.","journal-title":"Neuroscience"},{"key":"1881_CR153","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-019-42633-9","volume":"9","author":"H Amani","year":"2019","unstructured":"Amani H, Habibey R, Shokri F, Hajmiresmail SJ, Akhavan O, Mashaghi A, et al. Selenium nanoparticles for targeted stroke therapy through modulation of inflammatory and metabolic signaling. Sci Rep. 2019;9:1\u201315. https:\/\/doi.org\/10.1038\/s41598-019-42633-9.","journal-title":"Sci Rep"},{"key":"1881_CR154","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-022-01082-z","volume":"7","author":"H Xu","year":"2022","unstructured":"Xu H, Li S, Liu YS. Nanoparticles in the diagnosis and treatment of vascular aging and related diseases. Signal Transduct Target Ther. 2022;7:1\u201337. https:\/\/doi.org\/10.1038\/s41392-022-01082-z.","journal-title":"Signal Transduct Target Ther"},{"key":"1881_CR155","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S0167-7799(98)01220-7","volume":"16","author":"DD Lasic","year":"1998","unstructured":"Lasic DD. Novel applications of liposomes. Trends Biotechnol. 1998;16:307\u201321. https:\/\/doi.org\/10.1016\/S0167-7799(98)01220-7.","journal-title":"Trends Biotechnol"},{"key":"1881_CR156","doi-asserted-by":"publisher","first-page":"846065","DOI":"10.3389\/FMEDT.2022.846065\/BIBTEX","volume":"4","author":"N Milo\u0161evi\u0107","year":"2022","unstructured":"Milo\u0161evi\u0107 N, R\u00fctter M, David A. Endothelial cell adhesion molecules- (un)attainable targets for nanomedicines. Front Med Technol. 2022;4:846065. https:\/\/doi.org\/10.3389\/FMEDT.2022.846065\/BIBTEX.","journal-title":"Front Med Technol"},{"key":"1881_CR157","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.3390\/PHARMACEUTICS13071004","volume":"13","author":"CMA Van Alem","year":"2021","unstructured":"Van Alem CMA, Metselaar JM, Van Kooten C, Rotmans JI. Recent advances in liposomal-based anti-inflammatory therapy. Pharmaceutics. 2021;13:1004. https:\/\/doi.org\/10.3390\/PHARMACEUTICS13071004.","journal-title":"Pharmaceutics"},{"key":"1881_CR158","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/J.JCONREL.2013.12.035","volume":"177","author":"MD Howard","year":"2014","unstructured":"Howard MD, Greineder CF, Hood ED, Muzykantov VR. Endothelial targeting of liposomes encapsulating SOD\/Catalase mimetic EUK-134 alleviates acute pulmonary inflammation. J Control Release. 2014;177:34. https:\/\/doi.org\/10.1016\/J.JCONREL.2013.12.035.","journal-title":"J Control Release"},{"key":"1881_CR159","doi-asserted-by":"publisher","first-page":"11421","DOI":"10.1073\/PNAS.93.21.11421","volume":"93","author":"VJ Dzau","year":"1996","unstructured":"Dzau VJ, Mann MJ, Morishita R, Kaneda Y. Fusigenic viral liposome for gene therapy in cardiovascular diseases. Proc Natl Acad Sci U S A. 1996;93:11421. https:\/\/doi.org\/10.1073\/PNAS.93.21.11421.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1881_CR160","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1161\/01.CIR.91.2.541","volume":"91","author":"EG Nabel","year":"1995","unstructured":"Nabel EG. Gene therapy for cardiovascular disease. Circulation. 1995;91:541\u20138. https:\/\/doi.org\/10.1161\/01.CIR.91.2.541.","journal-title":"Circulation"},{"key":"1881_CR161","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.1172\/JCI116496","volume":"91","author":"R Morishita","year":"1993","unstructured":"Morishita R, Gibbons GH, Kaneda Y, Ogihara T, Dzau VJ. Novel and effective gene transfer technique for study of vascular renin angiotensin system. J Clin Invest. 1993;91:2580\u20135. https:\/\/doi.org\/10.1172\/JCI116496.","journal-title":"J Clin Invest"},{"key":"1881_CR162","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1172\/JCI115970","volume":"90","author":"G Leclerc","year":"1992","unstructured":"Leclerc G, Gal D, Takeshita S, Nikol S, Weir L, Isner JM. Percutaneous arterial gene transfer in a rabbit model. Efficiency in normal and balloon-dilated atherosclerotic arteries. J Clin Invest. 1992;90:936\u201344. https:\/\/doi.org\/10.1172\/JCI115970.","journal-title":"J Clin Invest."},{"key":"1881_CR163","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1161\/01.CIR.83.6.2007","volume":"83","author":"CS Lim","year":"1991","unstructured":"Lim CS, Chapman GD, Gammon RS, Muhlestein JB, Bauman RP, Stack RS, et al. Direct in vivo gene transfer into the coronary and peripheral vasculatures of the intact dog. Circulation. 1991;83:2007\u201311. https:\/\/doi.org\/10.1161\/01.CIR.83.6.2007.","journal-title":"Circulation"},{"key":"1881_CR164","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1161\/01.RES.71.1.27","volume":"71","author":"GD Chapman","year":"1992","unstructured":"Chapman GD, Lim CS, Gammon RS, Culp SC, Desper JS, Bauman RP, et al. Gene transfer into coronary arteries of intact animals with a percutaneous balloon catheter. Circ Res. 1992;71:27\u201333. https:\/\/doi.org\/10.1161\/01.RES.71.1.27.","journal-title":"Circ Res"},{"key":"1881_CR165","doi-asserted-by":"publisher","unstructured":"Di Francesco V, Di Francesco M, Palomba R, Brahmachari S, Decuzzi P, Ferreira M. Towards potent anti-inflammatory therapies in atherosclerosis: the case of methotrexate and colchicine combination into compartmentalized liposomes. J Drug Deliv Sci Technol. 2023;80. https:\/\/doi.org\/10.1016\/j.jddst.2023.104179.","DOI":"10.1016\/j.jddst.2023.104179"},{"key":"1881_CR166","doi-asserted-by":"publisher","first-page":"3817","DOI":"10.1016\/j.apsb.2023.06.005","volume":"13","author":"H Liu","year":"2023","unstructured":"Liu H, Wang H, Li Q, Wang Y, He Y, Li X, et al. LPS adsorption and inflammation alleviation by polymyxin B-modified liposomes for atherosclerosis treatment. Acta Pharm Sin B. 2023;13:3817\u201333. https:\/\/doi.org\/10.1016\/j.apsb.2023.06.005.","journal-title":"Acta Pharm Sin B"},{"key":"1881_CR167","doi-asserted-by":"publisher","first-page":"3461","DOI":"10.1039\/D2NR03280E","volume":"15","author":"D Ho","year":"2023","unstructured":"Ho D, Lynd TO, Jun C, Shin J, Millican RC, Estep BK, et al. MiR-146a encapsulated liposomes reduce vascular inflammatory responses through decrease of ICAM-1 expression, macrophage activation, and foam cell formation. Nanoscale. 2023;15:3461\u201374. https:\/\/doi.org\/10.1039\/D2NR03280E.","journal-title":"Nanoscale"},{"key":"1881_CR168","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1161\/CIRCRESAHA.119.315185","volume":"126","author":"C Boada","year":"2020","unstructured":"Boada C, Zinger A, Tsao C, Zhao P, Martinez JO, Hartman K, et al. Rapamycin-loaded biomimetic nanoparticles reverse vascular inflammation. Circ Res. 2020;126:25\u201337. https:\/\/doi.org\/10.1161\/CIRCRESAHA.119.315185.","journal-title":"Circ Res"},{"key":"1881_CR169","doi-asserted-by":"publisher","unstructured":"Boada CA, Zinger A, Rohen S, Martinez JO, Evangelopoulos M, Molinaro R, et al. LDL-based lipid nanoparticle derived for blood plasma accumulates preferentially in atherosclerotic plaque. Front Bioeng Biotechnol. 2021;9. https:\/\/doi.org\/10.3389\/FBIOE.2021.794676.","DOI":"10.3389\/FBIOE.2021.794676"},{"key":"1881_CR170","doi-asserted-by":"publisher","first-page":"2174206","DOI":"10.1080\/10717544.2023.2174206","volume":"30","author":"C Li","year":"2023","unstructured":"Li C, Wang Z, Lei H, Zhang D. Recent progress in nanotechnology-based drug carriers for resveratrol delivery. Drug Deliv. 2023;30:2174206. https:\/\/doi.org\/10.1080\/10717544.2023.2174206.","journal-title":"Drug Deliv"},{"key":"1881_CR171","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1007\/S12975-023-01125-9","volume":"15","author":"RG Thomas","year":"2024","unstructured":"Thomas RG, Kim JH, Kim JH, Yoon J, Choi KH, Jeong YY. Treatment of ischemic stroke by atorvastatin-loaded PEGylated liposome. Transl Stroke Res. 2024;15:388\u201398. https:\/\/doi.org\/10.1007\/S12975-023-01125-9.","journal-title":"Transl Stroke Res"},{"key":"1881_CR172","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1049\/NBT2.12018","volume":"15","author":"A Bose","year":"2021","unstructured":"Bose A, Burman DR, Sikdar B, Patra P. Nanomicelles: types, properties and applications in drug delivery. IET Nanobiotechnol. 2021;15:19. https:\/\/doi.org\/10.1049\/NBT2.12018.","journal-title":"IET Nanobiotechnol"},{"key":"1881_CR173","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S0168-3659(99)00248-5","volume":"65","author":"H Maeda","year":"2000","unstructured":"Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release. 2000;65:271\u201384. https:\/\/doi.org\/10.1016\/S0168-3659(99)00248-5.","journal-title":"J Control Release"},{"key":"1881_CR174","doi-asserted-by":"publisher","first-page":"11185","DOI":"10.1021\/JACS.3C01054","volume":"145","author":"Y Liang","year":"2023","unstructured":"Liang Y, Sullivan HL, Carrow K, Mesfin JM, Korpanty J, Worthington K, et al. Inflammation-responsive micellar nanoparticles from degradable polyphosphoramidates for targeted delivery to myocardial infarction. J Am Chem Soc. 2023;145:11185\u201394. https:\/\/doi.org\/10.1021\/JACS.3C01054.","journal-title":"J Am Chem Soc"},{"key":"1881_CR175","doi-asserted-by":"publisher","first-page":"43552","DOI":"10.1039\/C5RA04057D","volume":"5","author":"SN Nadig","year":"2015","unstructured":"Nadig SN, Dixit SK, Levey N, Esckilsen S, Miller K, Dennis W, et al. Immunosuppressive nano-therapeutic micelles downregulate endothelial cell inflammation and immunogenicity. RSC Adv. 2015;5:43552. https:\/\/doi.org\/10.1039\/C5RA04057D.","journal-title":"RSC Adv"},{"key":"1881_CR176","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1021\/MP500653Y","volume":"12","author":"J Nguyen","year":"2015","unstructured":"Nguyen J, Sievers R, Motion JPM, Kivim\u00e4e S, Fang Q, Lee RJ. Delivery of lipid micelles into infarcted myocardium using a lipid-linked matrix metalloproteinase targeting peptide. Mol Pharm. 2015;12:1150\u20137. https:\/\/doi.org\/10.1021\/MP500653Y.","journal-title":"Mol Pharm"},{"key":"1881_CR177","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1186\/1556-276X-9-247","volume":"9","author":"E Abbasi","year":"2014","unstructured":"Abbasi E, Aval SF, Akbarzadeh A, Milani M, Nasrabadi HT, Joo SW, et al. Dendrimers: synthesis, applications, and properties. Nanoscale Res Lett. 2014;9:247. https:\/\/doi.org\/10.1186\/1556-276X-9-247.","journal-title":"Nanoscale Res Lett"},{"key":"1881_CR178","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3390\/MA13010065","volume":"13","author":"A Santos","year":"2019","unstructured":"Santos A, Veiga F, Figueiras A. Dendrimers as pharmaceutical excipients: synthesis, properties, toxicity and biomedical applications. Materials. 2019;13:65. https:\/\/doi.org\/10.3390\/MA13010065.","journal-title":"Materials"},{"key":"1881_CR179","doi-asserted-by":"publisher","unstructured":"Tabarzad M, Ghorbani-Bidkorbeh F, Hosseinabadi T. Dendrimers as antiinflammatory prodrugs. Dendrimer-Based Nanotherapeutics. 2021:417\u201334. https:\/\/doi.org\/10.1016\/B978-0-12-821250-9.00022-6.","DOI":"10.1016\/B978-0-12-821250-9.00022-6"},{"key":"1881_CR180","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1163\/156856206778530696","volume":"17","author":"LJ Taite","year":"2006","unstructured":"Taite LJ, West JL. Poly(ethylene glycol)-lysine dendrimers for targeted delivery of nitric oxide. J Biomater Sci Polym Ed. 2006;17:1159\u201372. https:\/\/doi.org\/10.1163\/156856206778530696.","journal-title":"J Biomater Sci Polym Ed"},{"key":"1881_CR181","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/j.jconrel.2020.10.064","volume":"330","author":"Y Lee","year":"2021","unstructured":"Lee Y, Lee J, Kim M, Kim GY, Choi JS, Lee M. Brain gene delivery using histidine and arginine-modified dendrimers for ischemic stroke therapy. J Control Release. 2021;330:907\u201319. https:\/\/doi.org\/10.1016\/j.jconrel.2020.10.064.","journal-title":"J Control Release"},{"key":"1881_CR182","first-page":"184P","volume":"49","author":"A Hagooly","year":"2008","unstructured":"Hagooly A, Almutairi A, Rossin R, Shokeen M, Ananth A, Anderson C, et al. Evaluation of a RGD-dendrimer labeled with 76Br in hindlimb ischemia mouse model. J Nucl Med. 2008;49:184P-184P.","journal-title":"J Nucl Med"},{"key":"1881_CR183","first-page":"14","volume":"54","author":"M Makowski","year":"2010","unstructured":"Makowski M, Jansen C, Botnar R, Kim WY, Maintz D, Spuentrup E. Molecular MRI of atherosclerosis: from mouse to man. Medicamundi. 2010;54:14\u201324.","journal-title":"Medicamundi"},{"key":"1881_CR184","doi-asserted-by":"publisher","unstructured":"Zielinska A, Carreir\u00f3 F, Oliveira AM, Neves A, Pires B, Nagasamy Venkatesh D, et al. Polymeric nanoparticles: production, characterization, toxicology and ecotoxicology. Molecules. 2020;25. https:\/\/doi.org\/10.3390\/MOLECULES25163731.","DOI":"10.3390\/MOLECULES25163731"},{"key":"1881_CR185","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.3390\/POLYM15051123","volume":"15","author":"M Elmowafy","year":"2023","unstructured":"Elmowafy M, Shalaby K, Elkomy MH, Alsaidan OA, Gomaa HAM, Abdelgawad MA, et al. Polymeric nanoparticles for delivery of natural bioactive agents: recent advances and challenges. Polymers. 2023;15:1123. https:\/\/doi.org\/10.3390\/POLYM15051123.","journal-title":"Polymers"},{"key":"1881_CR186","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.3390\/NANO10071403","volume":"10","author":"B Begines","year":"2020","unstructured":"Begines B, Ortiz T, P\u00e9rez-Aranda M, Mart\u00ednez G, Merinero M, Arg\u00fcelles-Arias F, et al. Polymeric nanoparticles for drug delivery: recent developments and future prospects. Nanomaterials. 2020;10:1403. https:\/\/doi.org\/10.3390\/NANO10071403.","journal-title":"Nanomaterials"},{"key":"1881_CR187","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/J.ADDR.2015.09.012","volume":"99","author":"JS Suk","year":"2015","unstructured":"Suk JS, Xu Q, Kim N, Hanes J, Ensign LM. PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv Drug Deliv Rev. 2015;99:28. https:\/\/doi.org\/10.1016\/J.ADDR.2015.09.012.","journal-title":"Adv Drug Deliv Rev"},{"key":"1881_CR188","doi-asserted-by":"publisher","first-page":"999404","DOI":"10.3389\/FPHAR.2022.999404\/PDF","volume":"13","author":"F Yang","year":"2022","unstructured":"Yang F, Xue J, Wang G, Diao Q. Nanoparticle-based drug delivery systems for the treatment of cardiovascular diseases. Front Pharmacol. 2022;13:999404. https:\/\/doi.org\/10.3389\/FPHAR.2022.999404\/PDF.","journal-title":"Front Pharmacol"},{"key":"1881_CR189","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1080\/17425247.2021.1828339","volume":"18","author":"J Majumder","year":"2020","unstructured":"Majumder J, Minko T. Multifunctional and stimuli-responsive nanocarriers for targeted therapeutic delivery. Expert Opin Drug Deliv. 2020;18:205. https:\/\/doi.org\/10.1080\/17425247.2021.1828339.","journal-title":"Expert Opin Drug Deliv"},{"key":"1881_CR190","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/NANO10071403","volume":"10","author":"B Begines","year":"2020","unstructured":"Begines B, Ortiz T, P\u00e9rez-Aranda M, Mart\u00ednez G, Merinero M, Arg\u00fcelles-Arias F, et al. Polymeric nanoparticles for drug delivery: recent developments and future prospects. Nanomaterials. 2020;10:1\u201341. https:\/\/doi.org\/10.3390\/NANO10071403.","journal-title":"Nanomaterials"},{"key":"1881_CR191","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1161\/CIRCULATIONAHA.113.002870","volume":"129","author":"S Katsuki","year":"2014","unstructured":"Katsuki S, Matoba T, Nakashiro S, Sato K, Koga JI, Nakano K, et al. Nanoparticle-mediated delivery of pitavastatin inhibits atherosclerotic plaque destabilization\/rupture in mice by regulating the recruitment of inflammatory monocytes. Circulation. 2014;129:896\u2013906. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.113.002870.","journal-title":"Circulation"},{"key":"1881_CR192","doi-asserted-by":"publisher","first-page":"6519","DOI":"10.1021\/acsnano.9b08216","volume":"14","author":"H Kim","year":"2020","unstructured":"Kim H, Kim H, Kumar S, Kang DW, Jo H, Jo H, et al. Affinity-driven design of cargo-switching nanoparticles to leverage a cholesterol-rich microenvironment for atherosclerosis therapy. ACS Nano. 2020;14:6519\u201331. https:\/\/doi.org\/10.1021\/acsnano.9b08216.","journal-title":"ACS Nano"},{"key":"1881_CR193","doi-asserted-by":"publisher","unstructured":"Nakano Y, Matoba T, Tokutome M, Funamoto D, Katsuki S, Ikeda G, et al. Nanoparticle-mediated delivery of irbesartan induces cardioprotection from myocardial ischemia-reperfusion injury by antagonizing monocyte-mediated inflammation. Sci Rep. 2016;6. https:\/\/doi.org\/10.1038\/SREP29601.","DOI":"10.1038\/SREP29601"},{"key":"1881_CR194","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.2147\/IJN.S25175","volume":"6","author":"ZM Binsalamah","year":"2011","unstructured":"Binsalamah ZM, Paul A, Khan AA, Prakash S, Shum-Tim D. Intramyocardial sustained delivery of placental growth factor using nanoparticles as a vehicle for delivery in the rat infarct model. Int J Nanomed. 2011;6:2667. https:\/\/doi.org\/10.2147\/IJN.S25175.","journal-title":"Int J Nanomed"},{"key":"1881_CR195","doi-asserted-by":"publisher","first-page":"100972","DOI":"10.1016\/J.NANTOD.2020.100972","volume":"35","author":"H Huang","year":"2020","unstructured":"Huang H, Feng W, Chen Y, Shi J. Inorganic nanoparticles in clinical trials and translations. Nano Today. 2020;35:100972. https:\/\/doi.org\/10.1016\/J.NANTOD.2020.100972.","journal-title":"Nano Today"},{"key":"1881_CR196","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S11671-023-03943-0","volume":"18","author":"G Unnikrishnan","year":"2023","unstructured":"Unnikrishnan G, Joy A, Megha M, Kolanthai E, Senthilkumar M. Exploration of inorganic nanoparticles for revolutionary drug delivery applications: a critical\u00a0review. Discover Nano. 2023;18:1\u201344. https:\/\/doi.org\/10.1186\/S11671-023-03943-0.","journal-title":"Discover Nano"},{"key":"1881_CR197","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/S11671-023-03943-0","volume":"18","author":"G Unnikrishnan","year":"2023","unstructured":"Unnikrishnan G, Joy A, Megha M, Kolanthai E, Senthilkumar M. Exploration of inorganic nanoparticles for revolutionary drug delivery applications: a critical review. Discover Nano. 2023;18:157. https:\/\/doi.org\/10.1186\/S11671-023-03943-0.","journal-title":"Discover Nano"},{"key":"1881_CR198","doi-asserted-by":"publisher","first-page":"113820","DOI":"10.1016\/J.ADDR.2021.05.030","volume":"175","author":"Y Kang","year":"2021","unstructured":"Kang Y, Liu J, Jiang Y, Yin S, Huang Z, Zhang Y, et al. Understanding the interactions between inorganic-based nanomaterials and biological membranes. Adv Drug Deliv Rev. 2021;175:113820. https:\/\/doi.org\/10.1016\/J.ADDR.2021.05.030.","journal-title":"Adv Drug Deliv Rev"},{"key":"1881_CR199","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/S41573-018-0006-Z","volume":"18","author":"RS Riley","year":"2019","unstructured":"Riley RS, June CH, Langer R, Mitchell MJ. Delivery technologies for cancer immunotherapy. Nat Rev Drug Discov. 2019;18:175\u201396. https:\/\/doi.org\/10.1038\/S41573-018-0006-Z.","journal-title":"Nat Rev Drug Discov"},{"key":"1881_CR200","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/J.ACTBIO.2017.01.062","volume":"51","author":"Y Yan","year":"2017","unstructured":"Yan Y, Fu J, Wang T, Lu X. Controlled release of silyl ether camptothecin from thiol-ene click chemistry-functionalized mesoporous silica nanoparticles. Acta Biomater. 2017;51:471\u20138. https:\/\/doi.org\/10.1016\/J.ACTBIO.2017.01.062.","journal-title":"Acta Biomater"},{"key":"1881_CR201","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.3390\/IJMS19102875","volume":"19","author":"L Liu","year":"2018","unstructured":"Liu L, Cai R, Wang Y, Tao G, Ai L, Wang P, et al. Polydopamine-assisted silver nanoparticle self-assembly on sericin\/agar film for potential wound dressing application. Int J Mol Sci. 2018;19:2875. https:\/\/doi.org\/10.3390\/IJMS19102875.","journal-title":"Int J Mol Sci"},{"key":"1881_CR202","doi-asserted-by":"publisher","unstructured":"Gao W, Sun Y, Cai M, Zhao Y, Cao W, Liu Z, et al. Copper sulfide nanoparticles as a photothermal switch for TRPV1 signaling to attenuate atherosclerosis. Nat Commun. 2018;9. https:\/\/doi.org\/10.1038\/s41467-017-02657-z.","DOI":"10.1038\/s41467-017-02657-z"},{"key":"1881_CR203","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.bios.2016.07.047","volume":"88","author":"B Sun","year":"2017","unstructured":"Sun B, Gou Y, Ma Y, Zheng X, Bai R, Ahmed Abdelmoaty AA, et al. Investigate electrochemical immunosensor of cortisol based on gold nanoparticles\/magnetic functionalized reduced graphene oxide. Biosens Bioelectron. 2017;88:55\u201362. https:\/\/doi.org\/10.1016\/j.bios.2016.07.047.","journal-title":"Biosens Bioelectron"},{"key":"1881_CR204","doi-asserted-by":"publisher","first-page":"24338","DOI":"10.1021\/acsomega.1c01506","volume":"6","author":"A Arizmendi-Grijalva","year":"2021","unstructured":"Arizmendi-Grijalva A, Mart\u00ednez-Higuera AA, Soto-Guzm\u00e1n JA, Mart\u00ednez-Soto JM, Rodr\u00edguez-Le\u00f3n E, Rodr\u00edguez-Beas C, et al. Effect on human vascular endothelial cells of Au nanoparticles synthesized fromvitex mollis. ACS Omega. 2021;6:24338\u201350. https:\/\/doi.org\/10.1021\/acsomega.1c01506.","journal-title":"ACS Omega"},{"key":"1881_CR205","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/J.JCONREL.2012.08.031","volume":"163","author":"ED Hood","year":"2012","unstructured":"Hood ED, Greineder CF, Dodia C, Han J, Mesaros C, Shuvaev VV, et al. Antioxidant protection by PECAM-targeted delivery of a novel NADPH-oxidase inhibitor to the endothelium in vitro and in vivo. J Control Release. 2012;163:161\u20139. https:\/\/doi.org\/10.1016\/J.JCONREL.2012.08.031.","journal-title":"J Control Release"},{"key":"1881_CR206","doi-asserted-by":"publisher","first-page":"95","DOI":"10.3109\/08982101003754401","volume":"21","author":"S Hua","year":"2011","unstructured":"Hua S, Chang HI, Davies NM, Cabot PJ. Targeting of ICAM-1\u2013directed immunoliposomes specifically to activated endothelial cells with low cellular uptake: use of an optimized procedure for the coupling of low concentrations of antibody to liposomes. J Liposome Res. 2011;21:95\u2013105. https:\/\/doi.org\/10.3109\/08982101003754401.","journal-title":"J Liposome Res"},{"key":"1881_CR207","doi-asserted-by":"publisher","first-page":"e2114842118","DOI":"10.1073\/PNAS.2114842118\/SUPPL_FILE\/PNAS.2114842118.SAPP.PDF","volume":"118","author":"Z Zhou","year":"2021","unstructured":"Zhou Z, Yeh CF, Mellas M, Oh MJ, Zhu J, Li J, et al. Targeted polyelectrolyte complex micelles treat vascular complications in vivo. Proc Natl Acad Sci U S A. 2021;118:e2114842118. https:\/\/doi.org\/10.1073\/PNAS.2114842118\/SUPPL_FILE\/PNAS.2114842118.SAPP.PDF.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1881_CR208","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.2967\/JNUMED.118.225169","volume":"60","author":"LA Perkins","year":"2019","unstructured":"Perkins LA, Anderson CJ, Novelli EM. Targeting P-selectin adhesion molecule in molecular imaging: P-selectin expression as a valuable imaging biomarker of inflammation in cardiovascular disease. J Nucl Med. 2019;60:1691. https:\/\/doi.org\/10.2967\/JNUMED.118.225169.","journal-title":"J Nucl Med"},{"key":"1881_CR209","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1093\/eurheartj\/ehaa770","volume":"42","author":"A Akhmedov","year":"2021","unstructured":"Akhmedov A, Sawamura T, Chen C-H, Kraler S, Vdovenko D, L\u00fcscher TF. Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1): a crucial driver of atherosclerotic cardiovascular disease. Eur Heart J. 2021;42:1797\u2013807. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa770.","journal-title":"Eur Heart J"},{"key":"1881_CR210","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1007\/S10571-009-9368-4","volume":"29","author":"J Benicky","year":"2009","unstructured":"Benicky J, S\u00e1nchez-Lemus E, Pavel J, Saavedra JM. Anti-inflammatory effects of angiotensin receptor blockers in the brain and the periphery. Cell Mol Neurobiol. 2009;29:781\u201392. https:\/\/doi.org\/10.1007\/S10571-009-9368-4.","journal-title":"Cell Mol Neurobiol"},{"key":"1881_CR211","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/J.JCONREL.2018.06.001","volume":"283","author":"Y Jiang","year":"2018","unstructured":"Jiang Y, Hardie J, Liu Y, Ray M, Luo X, Das R, et al. Nanocapsule-mediated cytosolic siRNA delivery for anti-inflammatory treatment. J Control Release. 2018;283:235\u201340. https:\/\/doi.org\/10.1016\/J.JCONREL.2018.06.001.","journal-title":"J Control Release"},{"key":"1881_CR212","doi-asserted-by":"publisher","first-page":"4804","DOI":"10.3390\/IJMS22094804","volume":"22","author":"VQ Sier","year":"2021","unstructured":"Sier VQ, van der Vorst JR, Quax PHA, de Vries MR, Zonoobi E, Vahrmeijer AL, et al. Endoglin\/CD105-based imaging of cancer and cardiovascular diseases: a systematic review. Int J Mol Sci. 2021;22:4804. https:\/\/doi.org\/10.3390\/IJMS22094804.","journal-title":"Int J Mol Sci"},{"key":"1881_CR213","doi-asserted-by":"publisher","first-page":"5840","DOI":"10.3390\/IJMS21165840","volume":"21","author":"W Olejarz","year":"2020","unstructured":"Olejarz W, Kubiak-Tomaszewska G, Chrzanowska A, Lorenc T. Exosomes in angiogenesis and anti-angiogenic therapy in cancers. Int J Mol Sci. 2020;21:5840. https:\/\/doi.org\/10.3390\/IJMS21165840.","journal-title":"Int J Mol Sci"},{"key":"1881_CR214","doi-asserted-by":"publisher","first-page":"114863","DOI":"10.1016\/J.ADDR.2023.114863","volume":"200","author":"H Yukawa","year":"2023","unstructured":"Yukawa H, Sato K, Baba Y. Theranostics applications of quantum dots in regenerative medicine, cancer medicine, and infectious diseases. Adv Drug Deliv Rev. 2023;200:114863. https:\/\/doi.org\/10.1016\/J.ADDR.2023.114863.","journal-title":"Adv Drug Deliv Rev"},{"key":"1881_CR215","doi-asserted-by":"publisher","first-page":"126","DOI":"10.3390\/VACCINES13020126","volume":"13","author":"S Ahmadivand","year":"2025","unstructured":"Ahmadivand S, Saleh M, El-Moghazy A, Elgohary AH, Saber WIA, Helmy YA. Revolutionizing nanovaccines: a new era of immunization. Vaccines. 2025;13:126. https:\/\/doi.org\/10.3390\/VACCINES13020126.","journal-title":"Vaccines"},{"key":"1881_CR216","doi-asserted-by":"publisher","unstructured":"Garc\u00eda-Pinel B, Porras-Alcal\u00e1 C, Ortega-Rodr\u00edguez A, Sarabia F, Prados J, Melguizo C, et al. Lipid-based nanoparticles: application and recent advances in cancer treatment. Nanomaterials. 2019;9. https:\/\/doi.org\/10.3390\/NANO9040638.","DOI":"10.3390\/NANO9040638"},{"key":"1881_CR217","doi-asserted-by":"publisher","first-page":"199","DOI":"10.3109\/10717544.2013.877100","volume":"22","author":"V Pandey","year":"2015","unstructured":"Pandey V, Gajbhiye KR, Soni V. Lactoferrin-appended solid lipid nanoparticles of paclitaxel for effective management of bronchogenic carcinoma. Drug Deliv. 2015;22:199\u2013205. https:\/\/doi.org\/10.3109\/10717544.2013.877100.","journal-title":"Drug Deliv"},{"key":"1881_CR218","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.3109\/10717544.2015.1074765","volume":"23","author":"J Singh","year":"2016","unstructured":"Singh J, Garg T, Rath G, Goyal AK. Advances in nanotechnology-based carrier systems for targeted delivery of bioactive drug molecules with special emphasis on immunotherapy in drug resistant tuberculosis - a critical review. Drug Deliv. 2016;23:1676\u201398. https:\/\/doi.org\/10.3109\/10717544.2015.1074765.","journal-title":"Drug Deliv"},{"key":"1881_CR219","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1556\/1646.11.2019.04","volume":"11","author":"A Maurya","year":"2019","unstructured":"Maurya A, Singh AK, Mishra G, Kumari K, Rai A, Sharma B, et al. Strategic use of nanotechnology in drug targeting and its consequences on human health: a focused review. Interv Med Appl Sci. 2019;11:38. https:\/\/doi.org\/10.1556\/1646.11.2019.04.","journal-title":"Interv Med Appl Sci"},{"key":"1881_CR220","doi-asserted-by":"publisher","first-page":"122753","DOI":"10.1016\/J.IJPHARM.2023.122753","volume":"635","author":"P Knoll","year":"2023","unstructured":"Knoll P, Francesco Racaniello G, Laquintana V, Veider F, Saleh A, Seybold A, et al. Lipid-based nanoparticles: enhanced cellular uptake via surface thiolation. Int J Pharm. 2023;635:122753. https:\/\/doi.org\/10.1016\/J.IJPHARM.2023.122753.","journal-title":"Int J Pharm"},{"key":"1881_CR221","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.3390\/PHARMACEUTICS14102086\/S1","volume":"14","author":"Y He","year":"2022","unstructured":"He Y, Bi D, Plantinga JA, Molema G, Bussmann J, Kamps JAAM. Development of a combined lipid-based nanoparticle formulation for enhanced siRNA delivery to vascular endothelial cells. Pharmaceutics. 2022;14:2086. https:\/\/doi.org\/10.3390\/PHARMACEUTICS14102086\/S1.","journal-title":"Pharmaceutics"},{"key":"1881_CR222","doi-asserted-by":"publisher","unstructured":"Alcantara KP, Malabanan JWT, Nalinratana N, Thitikornpong W, Rojsitthisak P, Rojsitthisak P. Cannabidiol-loaded solid lipid nanoparticles ameliorate the inhibition of proinflammatory cytokines and free radicals in an in vitro inflammation-induced cell model. Int J Mol Sci. 2024;25. https:\/\/doi.org\/10.3390\/ijms25094744.","DOI":"10.3390\/ijms25094744"},{"key":"1881_CR223","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/S12265-014-9605-1","volume":"8","author":"M Tadin-Strapps","year":"2015","unstructured":"Tadin-Strapps M, Robinson M, Le Voci L, Andrews L, Yendluri S, Williams S, et al. Development of lipoprotein(a) siRNAs for mechanism of action studies in non-human primate models of atherosclerosis. J Cardiovasc Transl Res. 2015;8:44\u201353. https:\/\/doi.org\/10.1007\/S12265-014-9605-1.","journal-title":"J Cardiovasc Transl Res"},{"key":"1881_CR224","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1038\/NBT.1989","volume":"29","author":"F Leuschner","year":"2011","unstructured":"Leuschner F, Dutta P, Gorbatov R, Novobrantseva TI, Donahoe JS, Courties G, et al. Therapeutic siRNA silencing in inflammatory monocytes. Nat Biotechnol. 2011;29:1005. https:\/\/doi.org\/10.1038\/NBT.1989.","journal-title":"Nat Biotechnol"},{"key":"1881_CR225","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1080\/10717544.2020.1785052","volume":"27","author":"M Zhang","year":"2020","unstructured":"Zhang M, Zhu NW, Ma WC, Chen MJ, Zheng L. Combined treatment with ultrasound-targeted microbubble destruction technique and NM-aFGF-loaded PEG-nanoliposomes protects against diabetic cardiomyopathy-induced oxidative stress by activating the AKT\/GSK-3\u03b21\/Nrf-2 pathway. Drug Deliv. 2020;27:938\u201352. https:\/\/doi.org\/10.1080\/10717544.2020.1785052.","journal-title":"Drug Deliv"},{"key":"1881_CR226","doi-asserted-by":"publisher","first-page":"2101207","DOI":"10.1002\/SMLL.202101207","volume":"17","author":"SP Kwon","year":"2021","unstructured":"Kwon SP, Hwang BH, Park EH, Kim HY, Lee JR, Kang M, et al. Nanoparticle-mediated blocking of excessive inflammation for prevention of heart failure following myocardial infarction. Small. 2021;17:2101207. https:\/\/doi.org\/10.1002\/SMLL.202101207.","journal-title":"Small"},{"key":"1881_CR227","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1161\/STROKEAHA.107.481788","volume":"38","author":"A Saleh","year":"2007","unstructured":"Saleh A, Schroeter M, Ringelstein A, Hartung HP, Siebler M, M\u00f6dder U, et al. Iron oxide particle-enhanced MRI suggests variability of brain inflammation at early stages after ischemic stroke. Stroke. 2007;38:2733\u20137. https:\/\/doi.org\/10.1161\/STROKEAHA.107.481788.","journal-title":"Stroke"},{"key":"1881_CR228","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/J.NANO.2015.02.021","volume":"11","author":"FM van der Valk","year":"2015","unstructured":"van der Valk FM, van Wijk DF, Lobatto ME, Verberne HJ, Storm G, Willems MCM, et al. Prednisolone-containing liposomes accumulate in human atherosclerotic macrophages upon intravenous administration. Nanomedicine. 2015;11:1039. https:\/\/doi.org\/10.1016\/J.NANO.2015.02.021.","journal-title":"Nanomedicine"},{"key":"1881_CR229","doi-asserted-by":"publisher","unstructured":"Delbaere Q, Chapet N, Huet F, Delmas C, Mewton N, Prunier F, et al. Anti-inflammatory drug candidates for prevention and treatment of cardiovascular diseases. Pharmaceuticals 2023;16. https:\/\/doi.org\/10.3390\/PH16010078.","DOI":"10.3390\/PH16010078"},{"key":"1881_CR230","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1002\/CLC.20066","volume":"30","author":"J Margolis","year":"2007","unstructured":"Margolis J, McDonald J, Heuser R, Klinke P, Waksman R, Virmani R, et al. Systemic nanoparticle paclitaxel (nab-Paclitaxel) for in-stent restenosis I (SNAPIST-I): a first-in-human safety and dose-finding study. Clin Cardiol. 2007;30:165. https:\/\/doi.org\/10.1002\/CLC.20066.","journal-title":"Clin Cardiol"},{"key":"1881_CR231","doi-asserted-by":"publisher","unstructured":"Suresh P, Salem-Bekhit MM, Veedu HP, Alshehri S, Nair SC, Bukhari SI, et al. Development of a novel methotrexate-loaded nanoemulsion for rheumatoid arthritis treatment with site-specific targeting subcutaneous delivery. Nanomaterials 2022;12. https:\/\/doi.org\/10.3390\/NANO12081299.","DOI":"10.3390\/NANO12081299"},{"key":"1881_CR232","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.2967\/JNUMED.115.166751","volume":"57","author":"HP Luehmann","year":"2016","unstructured":"Luehmann HP, Detering L, Fors BP, Pressly ED, Woodard PK, Randolph GJ, et al. PET\/CT imaging of chemokine receptors in inflammatory atherosclerosis using targeted nanoparticles. J Nucl Med. 2016;57:1124\u20139. https:\/\/doi.org\/10.2967\/JNUMED.115.166751.","journal-title":"J Nucl Med"},{"key":"1881_CR233","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1007\/S13346-021-01024-2","volume":"12","author":"S \u0110or\u0111evi\u0107","year":"2021","unstructured":"\u0110or\u0111evi\u0107 S, Gonzalez MM, Conejos-S\u00e1nchez I, Carreira B, Pozzi S, Ac\u00farcio RC, et al. Current hurdles to the translation of nanomedicines from bench to the clinic. Drug Deliv Transl Res. 2021;12:500. https:\/\/doi.org\/10.1007\/S13346-021-01024-2.","journal-title":"Drug Deliv Transl Res"},{"key":"1881_CR234","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12951-024-02901-X","volume":"22","author":"X Ma","year":"2024","unstructured":"Ma X, Tian Y, Yang R, Wang H, Allahou LW, Chang J, et al. Nanotechnology in healthcare, and its safety and environmental risks. J Nanobiotechnol. 2024;22:1\u201381. https:\/\/doi.org\/10.1186\/S12951-024-02901-X.","journal-title":"J Nanobiotechnol"},{"key":"1881_CR235","doi-asserted-by":"publisher","first-page":"1544393","DOI":"10.3389\/FMED.2025.1544393","volume":"12","author":"FD Rodr\u00edguez-G\u00f3mez","year":"2025","unstructured":"Rodr\u00edguez-G\u00f3mez FD, Monferrer D, Penon O, Rivera-Gil P. Regulatory pathways and guidelines for nanotechnology-enabled health products: a comparative review of EU and US frameworks. Front Med (Lausanne). 2025;12:1544393. https:\/\/doi.org\/10.3389\/FMED.2025.1544393.","journal-title":"Front Med (Lausanne)"},{"key":"1881_CR236","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.3390\/PHARMACEUTICS14091940\/S1","volume":"14","author":"K Osouli-Bostanabad","year":"2022","unstructured":"Osouli-Bostanabad K, Puliga S, Serrano DR, Bucchi A, Halbert G, Lalatsa A. Microfluidic manufacture of lipid-based nanomedicines. Pharmaceutics. 2022;14:1940. https:\/\/doi.org\/10.3390\/PHARMACEUTICS14091940\/S1.","journal-title":"Pharmaceutics"},{"issue":"2","key":"1881_CR237","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41573-020-0090-8","volume":"20","author":"MJ Mitchell","year":"2020","unstructured":"Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2020;20(2):101\u201324. https:\/\/doi.org\/10.1038\/s41573-020-0090-8.","journal-title":"Nat Rev Drug Discov"},{"key":"1881_CR238","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12951-022-01605-4","volume":"20","author":"S Waheed","year":"2022","unstructured":"Waheed S, Li Z, Zhang F, Chiarini A, Armato U, Wu J. Engineering nano-drug biointerface to overcome biological barriers toward precision drug delivery. J Nanobiotechnol. 2022;20:1\u201325. https:\/\/doi.org\/10.1186\/S12951-022-01605-4.","journal-title":"J Nanobiotechnol"},{"key":"1881_CR239","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/J.ADDR.2020.07.017","volume":"154\u2013155","author":"C P\u00e9rez-Medina","year":"2020","unstructured":"P\u00e9rez-Medina C, Teunissen AJP, Kluza E, Mulder WJM, van der Meel R. Nuclear imaging approaches facilitating nanomedicine translation. Adv Drug Deliv Rev. 2020;154\u2013155:123\u201341. https:\/\/doi.org\/10.1016\/J.ADDR.2020.07.017.","journal-title":"Adv Drug Deliv Rev"},{"key":"1881_CR240","doi-asserted-by":"publisher","first-page":"100511","DOI":"10.1016\/J.RESPLU.2023.100511","volume":"17","author":"LW Andersen","year":"2024","unstructured":"Andersen LW, Vammen L, Granfeldt A. Animal research in cardiac arrest. Resusc Plus. 2024;17:100511. https:\/\/doi.org\/10.1016\/J.RESPLU.2023.100511.","journal-title":"Resusc Plus"},{"key":"1881_CR241","doi-asserted-by":"publisher","first-page":"8830200","DOI":"10.1155\/2020\/8830200","volume":"2020","author":"M Senbekov","year":"2020","unstructured":"Senbekov M, Saliev T, Bukeyeva Z, Almabayeva A, Zhanaliyeva M, Aitenova N, et al. The recent progress and applications of digital technologies in healthcare: a review. Int J Telemed Appl. 2020;2020:8830200. https:\/\/doi.org\/10.1155\/2020\/8830200.","journal-title":"Int J Telemed Appl"}],"container-title":["Drug Delivery and Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-025-01881-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13346-025-01881-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-025-01881-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,7]],"date-time":"2025-12-07T21:50:10Z","timestamp":1765144210000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13346-025-01881-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,10]]},"references-count":241,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["1881"],"URL":"https:\/\/doi.org\/10.1007\/s13346-025-01881-1","relation":{},"ISSN":["2190-393X","2190-3948"],"issn-type":[{"value":"2190-393X","type":"print"},{"value":"2190-3948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,10]]},"assertion":[{"value":"13 May 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"We confirm that this manuscript has not been published elsewhere, nor is it under consideration by any other publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}